<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Biol Macromol</journal-id><journal-id journal-id-type="iso-abbrev">Int J Biol Macromol</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>International Journal of Biological Macromolecules</journal-title></journal-title-group><issn pub-type="ppub">0141-8130</issn><issn pub-type="epub">1879-0003</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8364403</article-id><article-id pub-id-type="pmcid-ver">PMC8364403.1</article-id><article-id pub-id-type="pmcaid">8364403</article-id><article-id pub-id-type="pmcaiid">8364403</article-id><article-id pub-id-type="pmid">34403674</article-id><article-id pub-id-type="doi">10.1016/j.ijbiomac.2021.08.076</article-id><article-id pub-id-type="pii">S0141-8130(21)01735-9</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review</article-title></title-group><contrib-group><contrib contrib-type="author" id="au0005"><name name-style="western"><surname>Fathizadeh</surname><given-names initials="H">Hadis</given-names></name><xref rid="af0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="au0010"><name name-style="western"><surname>Afshar</surname><given-names initials="S">Saman</given-names></name><xref rid="af0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au0015"><name name-style="western"><surname>Masoudi</surname><given-names initials="MR">Mahmood Reza</given-names></name><xref rid="af0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="au0020"><name name-style="western"><surname>Gholizadeh</surname><given-names initials="P">Pourya</given-names></name><xref rid="af0020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au0025"><name name-style="western"><surname>Asgharzadeh</surname><given-names initials="M">Mohammad</given-names></name><xref rid="af0025" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au0030"><name name-style="western"><surname>Ganbarov</surname><given-names initials="K">Khudaverdi</given-names></name><xref rid="af0030" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au0035"><name name-style="western"><surname>K&#246;se</surname><given-names initials="&#x15E;">&#350;&#252;kran</given-names></name><xref rid="af0035" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au0040"><name name-style="western"><surname>Yousefi</surname><given-names initials="M">Mehdi</given-names></name><xref rid="af0040" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au0045"><name name-style="western"><surname>Kafil</surname><given-names initials="HS">Hossein Samadi</given-names></name><xref rid="af0045" ref-type="aff">i</xref><xref rid="cr0005" ref-type="corresp">&#8270;</xref></contrib><aff id="af0005"><label>a</label>Department of laboratory sciences, Sirjan School of Medical Sciences, Sirjan, Iran</aff><aff id="af0010"><label>b</label>Department of Animal Biology, Faculty of Natural Science, University of Tabriz, Tabriz, Iran</aff><aff id="af0015"><label>c</label>Department of Internal Medicine, Sirjan School of Medical Sciences, Sirjan, Iran</aff><aff id="af0020"><label>d</label>Research Center for Pharmaceutical Nanotechnology, Tabriz University of Medical Sciences, Iran</aff><aff id="af0025"><label>e</label>Biotechnology Research Center, Tabriz University of Medical Sciences, Iran</aff><aff id="af0030"><label>f</label>Department of Microbiology, Baku state University, Baku, Azerbaijan</aff><aff id="af0035"><label>g</label>Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Tepecik Training and Research Hospital, &#304;zmir, Turkey.</aff><aff id="af0040"><label>h</label>Stem Cell Research Center, Tabriz University of Medical Sciences, Iran</aff><aff id="af0045"><label>i</label>Drug Applied Research Center, Faculty of Medicine, Tabriz University of Medical Sciences, Iran</aff></contrib-group><author-notes><corresp id="cr0005"><label>&#8270;</label>Corresponding author at: Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.</corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2021</year></pub-date><volume>188</volume><issue-id pub-id-type="pmc-issue-id">387981</issue-id><fpage>740</fpage><lpage>750</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2021</year></date><date date-type="rev-recd"><day>7</day><month>8</month><year>2021</year></date><date date-type="accepted"><day>10</day><month>8</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>08</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>15</day><month>08</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-08 04:25:30.710"><day>08</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="ab0005"><p>The world has been suffering from COVID-19 disease for more than a year, and it still has a high mortality rate. In addition to the need to minimize transmission of the virus through non-pharmacological measures such as the use of masks and social distance, many efforts are being made to develop a variety of vaccines to prevent the disease worldwide. So far, several vaccines have reached the final stages of safety and efficacy in various phases of clinical trials, and some, such as Moderna/NIAID and BioNTech/Pfizer, have reported very high safety and protection. The important point is that comparing different vaccines is not easy because there is no set standard for measuring neutralization. In this study, we have reviewed the common platforms of COVID-19 vaccines and tried to present the latest reports on the effectiveness of these vaccines.</p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>Covid-19</kwd><kwd>Sars-Cov-2</kwd><kwd>Vaccine</kwd><kwd>Infection</kwd><kwd>Adenovirus</kwd><kwd>Inactivated</kwd><kwd>Effectiveness</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">Discovery of several cases of pneumonia in late 2019 in Wuhan, China, was the beginning of a major global catastrophe and a widespread pandemic <xref rid="bb0005" ref-type="bibr">[1]</xref>. On February 11 of the following year, the cause of this pandemic, which was a novel coronavirus, was named by the international virus classification commission as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the resulting disease was named by the World Health Organization (WHO) as Coronavirus Disease 2019 (COVID-19) <xref rid="bb0010" ref-type="bibr">[2]</xref>, <xref rid="bb0015" ref-type="bibr">[3]</xref>. Coronaviruses are a great family of viruses that cause various diseases in animals and humans. Seven viruses of the genus Alpha and beta coronavirus can cause disease in humans. Among these, three viruses that cause Middle East Respiratory Syndrome (MERS-CoV), Severe Acute Respiratory Syndrome (SARS-CoV), and SARS-CoV-2 are the most common coronavirus-related deaths in the world <xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>. COVID-19 disease has a wide range of clinical manifestations, from asymptomatic, mild symptoms to acute respiratory distress syndrome (ARDS) and death <xref rid="bb0030" ref-type="bibr">[6]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0040" ref-type="bibr">[8]</xref>. Mortality rate of this disease was reported to be 1&#8211;3%, and this rate was higher in elderly patients, especially in men <xref rid="bb0045" ref-type="bibr">[9]</xref>. It was also found that the mortality rate varies in different geographical areas, which may be due to different immune responses in people in different regions <xref rid="bb0050" ref-type="bibr">[10]</xref>, <xref rid="bb0055" ref-type="bibr">[11]</xref>. SARS and MERS were also found to have higher mortality rates in parts of the United States and Europe than in Southeast Asian countries <xref rid="bb0060" ref-type="bibr">[12]</xref>. So far, no definitive and completely treatment is available to treat this disease, and most of the treatment strategies used in the world are to reduce the symptoms of the disease and prevent the progression of the disease in the infected person <xref rid="bb0065" ref-type="bibr">[13]</xref>. One way to design effective drugs is to understand the virus cycle and its pathogenicity, which helps scientists achieve a specific drug <xref rid="bb0070" ref-type="bibr">[14]</xref>.</p><p id="p0010">Still, using a mask and observing the social season and washing your hands are the most common ways to prevent getting the virus. One way to prevent and control the disease was to use herd immunity, which is possible by obtaining natural immunity through infection, but experience has shown that the consequences of this method can be devastating <xref rid="bb0030" ref-type="bibr">[6]</xref>. In Sweden, where officials thought that by infecting 60% of the population, they could create a herd safety to protect the people of their country, this failed, and the death rate per million of the population infected with COVID-19 was at least 5 times higher than in Germany <xref rid="bb0075" ref-type="bibr">[15]</xref>. So, production of effective vaccines for providing long-term immunity is considered as the only principled way to create herd immunity. In this regard, many companies in different countries have made great progress in making new vaccines. The use of new methods and advanced technologies to produce a variety of vaccines, including RNA, DNA, virus-like particles, and subunit vaccines, has been widely tested <xref rid="bb0080" ref-type="bibr">[16]</xref>. In addition, in order to produce a safe and effective vaccine, it is critical to perform pre-clinical and clinical trials to thoroughly investigate and determine any side effects of these vaccines <xref rid="bb0085" ref-type="bibr">[17]</xref>. The purpose of this study is to review the different types of vaccines that are currently being produced and tested around the world, as well as the mechanism of action of these vaccines and the extent of progress and efficacy and safety of these vaccines.</p></sec><sec id="s0010"><label>2</label><title>Specific features of coronavirus for vaccine development</title><p id="p0015">SARS-CoV-2 is a spherical and positive-sense single-stranded RNA virus with a helical nucleocapsid. Size of SARS-CoV-2 genome is 30&#160;kb. One third of this genome is responsible for encoding the structural proteins of the virus, and the rest of the genome shows expression and replication <xref rid="bb0090" ref-type="bibr">[18]</xref>. Structure of this virus consists of membrane glycoproteins (M), spike proteins (S), hemagglutinin ester dimer proteins (HE), nucleocapsid proteins (N), and envelope proteins (E). The major coat glycoprotein expressed at the virus surface (S-protein) is the main target of vaccines <xref rid="bb0095" ref-type="bibr">[19]</xref>. S-protein consists of two subunits: S1 subunit is responsible for binding to the receptor and S2 subunit is responsible for fusion with the cell membrane <xref rid="bb0100" ref-type="bibr">[20]</xref>. The main receptor for SARS-CoV-2 entry into human cells is angiotensin-converting enzyme 2 (ACE2) identified by S-protein <xref rid="bb0105" ref-type="bibr">[21]</xref>. ACE2, an attached carboxypeptidase to the plasma membrane of kidney, intestines, testis, heart, lung and gallbladder cells, is consisting of a 17-amino-acid signal peptide at the amino terminal, a single metalloproteinase active site containing a zinc ion binding motif, a transmembrane domain, and a 22-amino acid small cytoplasmic domain at the carboxyl terminus <xref rid="bb0110" ref-type="bibr">[22]</xref>. The main activity of ACE2 is to lower blood pressure by converting angiotensin II to angiotensin I-VII <xref rid="bb0115" ref-type="bibr">[23]</xref>, <xref rid="bb0120" ref-type="bibr">[24]</xref>. It has also been shown that the epithelial expression of ACE2 in the small intestine and lung provides a pathway for SARS-CoV entry <xref rid="bb0125" ref-type="bibr">[25]</xref>. During SARS-CoV-2 outbreak, high expression of ACE2 was detected in type II alveolar cells of lung <xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>, <xref rid="bb0140" ref-type="bibr">[28]</xref>. The binding affinity of ACE2 and SARS-CoV-2 is approximately 10- to 20-fold higher than that affinity between ACE2 and SARS-CoV <xref rid="bb0145" ref-type="bibr">[29]</xref>, <xref rid="bb0150" ref-type="bibr">[30]</xref>. Genomic sequence of S-protein is really diverse among coronaviruses. This variation in S-protein is related to S1 subunit, which consists of two parts: a receptor-binding domain (RBD) and N-terminal domain (NTD) <xref rid="bb0100" ref-type="bibr">[20]</xref>. S-protein has a polybasic cleavage site between S1 and S2 parts which leads to the acquisition of three O-linked glycans around the site. The adjacent predicted O-linked glycans and polybasic cleavage sites have not been found in any of the previous beta-coronaviruses and are unique to the SARS-CoV-2 <xref rid="bb0095" ref-type="bibr">[19]</xref>, <xref rid="bb0155" ref-type="bibr">[31]</xref>. Binding of the S-protein to the ACE2 receptor and its proteolytic cleavage and integration with the membrane led to release viral RNA into the cytosol <xref rid="bb0155" ref-type="bibr">[31]</xref>, <xref rid="bb0160" ref-type="bibr">[32]</xref>. Unlike the S-protein, E and M proteins of SARS- CoV-2 have weak immune humoral responses, possibly due to their small molecular size and small ectodomines, which make them indistinguishable from immune cells <xref rid="bb0165" ref-type="bibr">[33]</xref>. One study found that transmitting serum from donors immunized with a viral vector expressing E and M protein did not provide any protection against coronary infection <xref rid="bb0170" ref-type="bibr">[34]</xref>. Because the neutralizing antibodies produced in COVID-19 patients are also more likely to be produced against S-protein epitopes, S-protein is a promising target for vaccination against the SARS-CoV-2 <xref rid="bb0175" ref-type="bibr">[35]</xref>. One of the important points in designing vaccines is knowing the isoelectric point. An isoelectric point (IEP or pI) is a pH value at which the net charge of a molecule or biomolecules is zero. Because the electrical repulsion and solubility are at a point lower than the pI, there is a greater tendency for precipitation and aggregation <xref rid="bb0180" ref-type="bibr">[36]</xref>. There is currently no accurate experimental data for isoelectric point of SARS-CoV-2, or its structural and nonstructural proteins. Using bioinformatics tools such as Ex-PASy can give us an isoelectric point prediction <xref rid="bb0185" ref-type="bibr">[37]</xref>. These predictions are based on the amino acid sequence, and it should be noted that bioinformatics tools cannot take into account the post-translational changes that occur in the amino acid sequence of proteins <xref rid="bb0190" ref-type="bibr">[38]</xref>. The pI values of the three SARS-CoV-2 proteins (S, E, and M) that are important in vaccine design are 6.24, 8.57, and 9.51, respectively <xref rid="bb0195" ref-type="bibr">[39]</xref>, <xref rid="bb0200" ref-type="bibr">[40]</xref>. The pH changes directly affect the isoelectric point and cause precipitation or insolubility. In one study, the stability of SARS-CoV-2 in different environmental conditions, in the exposure of different disinfectants, and at different pH was evaluated. This study reported that SARS-CoV-2 is stable in a wide range of pH, i.e., pH&#160;3-10 <xref rid="bb0205" ref-type="bibr">[41]</xref>. Another item that is important in inactivating SARS-CoV-2 is the lipophilic or hydrophilic nature of the virus. SARS-CoV-2 has lipophilic properties due to its lipid envelope, so it allows lipophilic disinfectants such as aldehydes, proteases, phenolics, peroxides, alcohols, and detergents to penetrate <xref rid="bb0210" ref-type="bibr">[42]</xref>. However, it should be noted that the penetration of a substance into the virus does not necessarily cause the loss of the mechanism of nucleic acid replication and virus replication <xref rid="bb0215" ref-type="bibr">[43]</xref>. Properly inactivating SARS-CoV-2 is very important in making vaccines. For example, if SARS-CoV-2 epitopes are destroyed during inactivation, we may have a very weak antibody response and therefore the vaccine may not be very protective. Also, if the virus is not completely deactivated, the viral prevalence may happen after vaccination <xref rid="bb0220" ref-type="bibr">[44]</xref>. In general, different designs for SARS-CoV-2 vaccines are currently being developed by large companies and are undergoing various stages of preclinical and clinical trials <xref rid="bb0225" ref-type="bibr">[45]</xref>, <xref rid="bb0230" ref-type="bibr">[46]</xref>, <xref rid="bb0235" ref-type="bibr">[47]</xref>, <xref rid="bb0240" ref-type="bibr">[48]</xref>, <xref rid="bb0245" ref-type="bibr">[49]</xref>, <xref rid="bb0250" ref-type="bibr">[50]</xref>. Some of these vaccines are based on inactivated viruses or subunits of the virus, and others are based on nucleic acids, each of which has advantages and limitations over the others. One classification that can be considered for these vaccines is based on whether the vaccines exert their immunogenicity as soon as they enter the host body or whether processes such as protein translation are required. Accordingly, inactivated vaccines and nanoparticles containing S-protein stimulate the immune system upon arrival, but vaccines based on nucleic acids and viral vectors must undergo the translation of nucleic acid into immunogenic protein within the host cell (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
<bold>)</bold>.<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Classification of common vaccines based on the translation process requirement for immunization.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p></sec><sec id="s0015"><label>3</label><title>Different designs of SARS-CoV-2 vaccines</title><sec id="s0020"><label>3.1</label><title>Inactivated vaccines</title><p id="p0020">Inactivated vaccines are the fastest option for antiviral vaccines, which are traditionally obtained from virus-infected cells. This method was first invented in 1940 using embryonated eggs to produce the flu vaccine <xref rid="bb0255" ref-type="bibr">[51]</xref>. To date, various chemical and physical methods, including the use of formalin, formaldehyde, &#946;-propiolactone and UV alone or a combination of these methods, have been used to inactivate coronaviruses <xref rid="bb0260" ref-type="bibr">[52]</xref>, <xref rid="bb0265" ref-type="bibr">[53]</xref>. Subunits of these inactivated viruses are commonly used to produce antibodies because the use of whole viruses increases the risk of reactogenicity. Tetanus and diphtheria vaccines are examples of subunit vaccines, and polio vaccine is a classic example of a whole killed virus vaccine <xref rid="bb0270" ref-type="bibr">[54]</xref>. Because these vaccines provide weaker immunity than live vaccines, the use of adjuvants is required to achieve an effective and robust immune response <xref rid="bb0275" ref-type="bibr">[55]</xref>. Several inactive SARS-CoV-2 vaccines are currently being developed rapidly <bold>(</bold>
<xref rid="t0005" ref-type="table">Table 1</xref>
<bold>)</bold>. A major problem in inactivating vaccines is the selection of the appropriate viral strain. In one study, it was reported that the CoronaVac inactivated vaccine with alum adjuvant had very acceptable neutralizing effects against the SARS-CoV-2 <xref rid="bb0280" ref-type="bibr">[56]</xref>. BBIBP-CorV is one of the inactivated vaccines that is made in Wuhan Institute of Biological Products (Sinopharm) and Beijing Institute of Biological Products, has passed the phase 3 clinical trial. The results of one research have shown that this type of vaccine has been safe and tolerated in all tested doses and in two age groups. Humoral immune responses against SARS-CoV-2 were induced in all recipients of vaccine on day 42. Also, this study reported that two-dose immunization with 4&#160;&#956;g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralizing antibodies titres than the single 8&#160;&#956;g dose or 4&#160;&#956;g dose on days 0 and 14 <xref rid="bb0285" ref-type="bibr">[57]</xref>. Although using of inactivated vaccines is one of the commonly immunization methods in worldwide, they also have drawbacks, for example, the use of aluminum hydroxide as an adjuvant has previously been linked to vaccine-associated enhanced respiratory disease (VAERD) <xref rid="bb0290" ref-type="bibr">[58]</xref>. However, so far no signs of VAERD have been noted in the performed SARS-CoV-2 clinical trials to date. Another concern with inactivated vaccines is their short immunity period. Previously inactivated vaccines against SARS-CoV showed that antiviral IgG levels dropped rapidly 16&#160;months after inoculation <xref rid="bb0295" ref-type="bibr">[59]</xref>.<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Different types of SARS-CoV-2 vaccine candidates and their effectiveness.</p></caption><alt-text id="al0015">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine type</th><th colspan="1" rowspan="1">Vaccine type and immunogenic</th><th colspan="1" rowspan="1">Vaccine name</th><th colspan="1" rowspan="1">Developers</th><th colspan="1" rowspan="1">Dose schedule</th><th colspan="1" rowspan="1">Cold chain required for storage</th><th colspan="1" rowspan="1">Efficacy</th><th colspan="1" rowspan="1">Registry index</th><th colspan="1" rowspan="1">Ref</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">CoronaVac</td><td colspan="1" rowspan="1">Sinovac Research and Development Co.</td><td colspan="1" rowspan="1">3&#160;&#956;g of CoronaVac in 0.5&#160;ml of diluent (two doses - day 0, day 14)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">Brazil study: where the prevalence of p.1 variant was more than 75%: efficacy was<break/>50.7%, 83.7% and 100% against mild, moderate and severe infection, respectively.<break/>Turkey study: 83.5% in 18-59&#160;years old volunteers<break/>Chile study: 65.9%, 87.5%, 90.3% and 86.3% against prevention of Covid-19, prevention of hospitalization, ICU admission and prevention of Covid-19 related death, respectively</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04456595" id="ir0005">NCT04456595</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04582344" id="ir0010">NCT04582344</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04617483" id="ir0015">NCT04617483</ext-link>, INA-WXFM0YX</td><td colspan="1" rowspan="1"><xref rid="bb0240" ref-type="bibr">[48]</xref>, <xref rid="bb0630" ref-type="bibr">[126]</xref>, <xref rid="bb0635" ref-type="bibr">[127]</xref>, <xref rid="bb0640" ref-type="bibr">[128]</xref></td></tr><tr><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">BBIBP-CorV</td><td colspan="1" rowspan="1">Beijing Institute of Biotechnology / China National Pharmaceutical Group Co. (Sinopharm)</td><td colspan="1" rowspan="1">4&#160;&#956;g (two doses - day 0, day 21)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">79%</td><td colspan="1" rowspan="1">ChiCTR2000034780, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04560881" id="ir0020">NCT04560881</ext-link>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04510207" id="ir0025">NCT04510207</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0285" ref-type="bibr">[57]</xref>, <xref rid="bb0645" ref-type="bibr">[129]</xref></td></tr><tr><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Not Reported</td><td colspan="1" rowspan="1">Wuhan Institute of Biological Products / China National Pharmaceutical Group Co. (Sinopharm)</td><td colspan="1" rowspan="1">Undisclosed quantity of dosage (two doses - day 0, day 21)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">ChiCTR2000034780, ChiCTR2000039000, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04612972" id="ir0030">NCT04612972</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04510207" id="ir0035">NCT04510207</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0235" ref-type="bibr">[47]</xref></td></tr><tr><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">BBV152 (Covaxin)</td><td colspan="1" rowspan="1">Bharat Biotech</td><td colspan="1" rowspan="1">6&#160;&#956;g (two doses - day 0, day 28)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">81%</td><td colspan="1" rowspan="1">CTRI/2020/11/028976</td><td colspan="1" rowspan="1"><break/><xref rid="bb0650" ref-type="bibr">[130]</xref>, <xref rid="bb0655" ref-type="bibr">[131]</xref></td></tr><tr><td rowspan="4" colspan="1">Non-Replicating Viral vector vaccine</td><td colspan="1" rowspan="1">Non-Replicating Ad5 vectored vaccine expressing the SARS-CoV-2 full length spike protein</td><td colspan="1" rowspan="1">Ad5-nCoV</td><td colspan="1" rowspan="1">CanSino Biological / Beijing institute of biotechnology / Academy of Military Medical Sciences</td><td colspan="1" rowspan="1">0.5&#160;&#215;&#160;10<sup>11</sup> vp (one dose)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04526990" id="ir0040">NCT04526990</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04540419" id="ir0045">NCT04540419</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0345" ref-type="bibr">[69]</xref>, <xref rid="bb0660" ref-type="bibr">[132]</xref></td></tr><tr><td colspan="1" rowspan="1">Non-Replicating Chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 full length spike protein</td><td colspan="1" rowspan="1">AZD1222 (ChAdOx1 nCoV-19)</td><td colspan="1" rowspan="1">AstraZeneca / Oxford University</td><td colspan="1" rowspan="1">3.5-6.5&#160;&#215;&#160;10<sup>10</sup> vp (two doses - day 0, day28)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">Half dose + standard dose: 90% Two standard dose: 62.1% Overall: 70.4%, Recent studies results:<break/>81.5% for non-B.1.1.7 variants, 70.4% for B.1.1.7 variant and 10.4% for B.1.351 variant,<break/>Single dose effectiveness against B.1.617.2 and B.1.1.7 variants: 33.5% and 51.1%, respectively.<break/>Two dose effectiveness against B.1.617.2 and B.1.1.7 variants: 59.8% and 66.1%, respectively.</td><td colspan="1" rowspan="1">ISRCTN89951424,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04516746" id="ir0050">NCT04516746</ext-link>,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04540393" id="ir0055">NCT04540393</ext-link>,<break/>CTRI/2020/08/<break/>027170</td><td colspan="1" rowspan="1"><xref rid="bb0225" ref-type="bibr">[45]</xref>, <xref rid="bb0230" ref-type="bibr">[46]</xref>, <xref rid="bb0330" ref-type="bibr">[66]</xref>, <xref rid="bb0630" ref-type="bibr">[126]</xref>, <xref rid="bb0665" ref-type="bibr">[133]</xref>, <xref rid="bb0670" ref-type="bibr">[134]</xref>, <xref rid="bb0675" ref-type="bibr">[135]</xref></td></tr><tr><td colspan="1" rowspan="1">Non-Replicating rAd6 and rAd5 both of them carry the SARS-CoV-2 full length spike protein gene</td><td colspan="1" rowspan="1">Gam-COVID-Vac (Sputnik V)</td><td colspan="1" rowspan="1">Gamaleya Research Institute of Epidemiology and Microbiology/ Russian Ministry of Health</td><td colspan="1" rowspan="1">10<sup>11</sup> vp (two doses - day 0, day21)</td><td colspan="1" rowspan="1">Two explanations:<break/>Frozen at -18&#160;&#176;C<break/>Lyophilized at 2-8&#160;&#176;C</td><td colspan="1" rowspan="1">91.6%</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04530396" id="ir0060">NCT04530396</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04564716" id="ir0065">NCT04564716</ext-link>,<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04642339" id="ir0070">NCT04642339</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0680" ref-type="bibr">[136]</xref>, <xref rid="bb0685" ref-type="bibr">[137]</xref></td></tr><tr><td colspan="1" rowspan="1">Non-Replicating Ad26 vectored vaccine carry the full-length spike protein gene with two proline substitutions and two mutations at furin cleavage site</td><td colspan="1" rowspan="1">JNJ-78436735(Ad26.COV2. S)</td><td colspan="1" rowspan="1">Janssen Pharmaceutical Companies</td><td colspan="1" rowspan="1">10<sup>11</sup> vp (one dose)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">66% against infection and 85% against severe-critical covid-19, against b.1.351 variant: 64% against moderate disease and 82% against severe-critical disease</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04505722" id="ir0075">NCT04505722</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04614948" id="ir0080">NCT04614948</ext-link>, <break/>ISRCTN14722499</td><td colspan="1" rowspan="1"><xref rid="bb0690" ref-type="bibr">[138]</xref>, <xref rid="bb0695" ref-type="bibr">[139]</xref>, <xref rid="bb0700" ref-type="bibr">[140]</xref>, <xref rid="bb0705" ref-type="bibr">[141]</xref>, <xref rid="bb0710" ref-type="bibr">[142]</xref></td></tr><tr><td rowspan="2" colspan="1">DNA vaccine</td><td colspan="1" rowspan="1">SARS-CoV-2 spike protein gene was cloned into the expression vector pGX0001</td><td colspan="1" rowspan="1">INO-4800</td><td colspan="1" rowspan="1">Coalition for Epidemic Preparedness Innovation (CEPI), Inovio Pharmace ticals</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">can be stored for 4.5&#160;years at 2&#8211;8&#160;&#176;C, room temperature for 1&#160;year and 1&#160;month at 37&#160;&#176;C</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04336410" id="ir0085">NCT04336410</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04642638" id="ir0090">NCT04642638</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04447781" id="ir0095">NCT04447781</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0395" ref-type="bibr">[79]</xref></td></tr><tr><td colspan="1" rowspan="1">SARS-CoV-2 spike protein gene was cloned into the pVAX-1 plasmid</td><td colspan="1" rowspan="1">ZyCoV-D</td><td colspan="1" rowspan="1">Cadila pharmaceuticals limited</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">CTRI/2020/07/026352</td><td colspan="1" rowspan="1"><xref rid="bb0715" ref-type="bibr">[143]</xref></td></tr><tr><td rowspan="2" colspan="1">mRNA vaccine</td><td colspan="1" rowspan="1">mRNA encoding the SARS CoV-2 full length spike protein (modified by two proline substitutions)</td><td colspan="1" rowspan="1">BNT162b2</td><td colspan="1" rowspan="1">Pfizer / BioNTech / Fosun pharma</td><td colspan="1" rowspan="1"><bold>30</bold>&#160;&#956;g (two doses - day 0, day 21)</td><td colspan="1" rowspan="1">Stable at: -70&#160;&#176;C for up to 6-month, 2-8&#160;&#176;C for 5&#160;days</td><td colspan="1" rowspan="1">95% overall, 94.7% (&gt;65&#160;years old), Israel vaccination results: 94%, Recent studies results:<break/>Single dose 80%<break/>Two doses 90%.<break/>In 12-15&#160;years old adolescents: 100%<break/>Single dose effectiveness against B.1.617.2 and B.1.1.7 variants: 33.5% and 51.1%, respectively.<break/>Two dose effectiveness against B.1.617.2 and B.1.1.7 variants: 87.9% and 93.4%, respectively/</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368728" id="ir0100">NCT04368728</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0245" ref-type="bibr">[49]</xref>, <xref rid="bb0460" ref-type="bibr">[92]</xref>, <xref rid="bb0675" ref-type="bibr">[135]</xref>, <xref rid="bb0720" ref-type="bibr">[144]</xref>, <xref rid="bb0725" ref-type="bibr">[145]</xref>, <xref rid="bb0730" ref-type="bibr">[146]</xref>, <xref rid="bb0735" ref-type="bibr">[147]</xref></td></tr><tr><td colspan="1" rowspan="1">mRNA encoding the SARS CoV-2 full length spike protein (modified by two proline substitutions)</td><td colspan="1" rowspan="1">mRNA-1273</td><td colspan="1" rowspan="1">Moderna / NIAID</td><td colspan="1" rowspan="1">100&#160;&#956;g of mRNA-1273 in a volume of 0.5&#160;ml (two doses - day 0, day 28)</td><td colspan="1" rowspan="1">Stable at: -20&#160;&#176;C for up to 6-month, 2-8&#160;&#176;C for up to 30&#160;days, room temperature(8-25&#160;&#176;C) for up to 12&#160;h</td><td colspan="1" rowspan="1">94.1%, Recent studies results: Single dose 80%<break/>Two doses 90%</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04470427" id="ir0105">NCT04470427</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0455" ref-type="bibr">[91]</xref>, <xref rid="bb0470" ref-type="bibr">[94]</xref>, <xref rid="bb0720" ref-type="bibr">[144]</xref>, <xref rid="bb0730" ref-type="bibr">[146]</xref>, <xref rid="bb0740" ref-type="bibr">[148]</xref></td></tr><tr><td colspan="1" rowspan="1">Protein subunit vaccine</td><td colspan="1" rowspan="1">Nanoparticle vaccine constructed from the Full-length spike protein with two proline substitutions and three mutations at furin cleavage site</td><td colspan="1" rowspan="1">NVX-CoV2373</td><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">5&#160;&#956;g of SARS-CoV-2 rs&#160;+&#160;50&#160;&#956;g of Matrix-M1 adjuvant (two doses - day 0, day 21)</td><td colspan="1" rowspan="1">2-8&#160;&#176;C</td><td colspan="1" rowspan="1">96.4% against non-B.1.1.7 variants, 86.3% against B.1.1.7 variant, 60% against B.1.351 variant</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04611802" id="ir0110">NCT04611802</ext-link>, 2020-004123-16</td><td colspan="1" rowspan="1"><xref rid="bb0250" ref-type="bibr">[50]</xref>, <xref rid="bb0745" ref-type="bibr">[149]</xref>, <xref rid="bb0750" ref-type="bibr">[150]</xref>, <xref rid="bb0755" ref-type="bibr">[151]</xref>, <xref rid="bb0760" ref-type="bibr">[152]</xref></td></tr><tr><td colspan="1" rowspan="1">Virus like particle vaccine (VLP)</td><td colspan="1" rowspan="1">Plant derived VLP displays multiple copies of SARS-CoV-2 spike protein on their surface + adjuvant</td><td colspan="1" rowspan="1">CoVLP</td><td colspan="1" rowspan="1">Medicago/Glaxo Smith Kline (GSK)</td><td colspan="1" rowspan="1">3.75&#160;&#956;g of CoVLP Vaccine adjuvanted with AS03 adjuvant (two doses - day 0, day 21) each arm will be injected once</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="ClinicalTrials.gov" xlink:href="NCT04636697" id="ir0115">NCT04636697</ext-link></td><td colspan="1" rowspan="1"><xref rid="bb0765" ref-type="bibr">[153]</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="s0025"><label>3.2</label><title>Non-replicating viral vector vaccine</title><p id="p0025">The use of viral vectors first began in 1972 with recombinant DNA from the SV40 virus. Subsequently, the vaccinia virus was introduced as a transient gene expression vector in 1982 <xref rid="bb0300" ref-type="bibr">[60]</xref>, <xref rid="bb0305" ref-type="bibr">[61]</xref>. Among the types of virally vectored candidates for non-replicating SARS-CoV-2 vaccines, most of them are based on adenoviruses. Adenoviruses are two-stranded DNA viruses that are inactivated by deleting their E1A and E1B gene region <xref rid="bb0310" ref-type="bibr">[62]</xref>. These vaccines induce strong immune responses and enhance both humoral and cellular immunity. Enteric adenovirus type 41 and adenovirus type 5 previously had been used against spike proteins of MERS-CoV, and acceptable immune responses, including both B-cell and T-cell responses, have been observed in vaccine recipients <xref rid="bb0315" ref-type="bibr">[63]</xref>. Adenovirus vectors are characterized by the easy growth of these viruses at high titers in cell lines, high expression of transgene, and great transduction effect, as well as a wide range of viral tropism <xref rid="bb0320" ref-type="bibr">[64]</xref>, <xref rid="bb0325" ref-type="bibr">[65]</xref>. Numerous clinical trials have been performed to evaluate the efficacy of adenoviral-vectored vaccines, some of which are listed in <xref rid="t0005" ref-type="table">Table 1</xref>. The results of clinical trials showed that nonreplicating vector vaccines are in good immunogenicity and safety. Also, the induction of antibodies against S-protein was confirmed by enzyme-linked immunosorbent assays (ELISA) in these studies <xref rid="bb0330" ref-type="bibr">[66]</xref>. One of the limitations of adenoviral-vectored vaccines is that most people have previous immunity to different strains of adenovirus (pathogens of upper respiratory infection) or they become immunized quickly after the first dose of vaccine <xref rid="bb0335" ref-type="bibr">[67]</xref>. For example, the results of a clinical trial based on Ad5vector-based HIV1 vaccine candidate failed due to patients&#8217; prior immunity against the Ad5 vector <xref rid="bb0340" ref-type="bibr">[68]</xref>. In the first randomised controlled trial for assessment of the immunogenicity of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, Zhu et al., demonstrated that is effective and safe, but they also reported that previous immunity to Ad5 and aging resulted in a slight decrease in vaccine efficacy in certain groups, especially in the case of hemorrhagic immune responses <xref rid="bb0345" ref-type="bibr">[69]</xref>. One way to overcome this problem is to use alternative adenoviral vectors such as Ad35, Ad26, and non-human adenovirus-derived vectors that are less common in humans <xref rid="bb0350" ref-type="bibr">[70]</xref>, <xref rid="bb0355" ref-type="bibr">[71]</xref>. AstraZeneca, Johnson &amp; Johnson, and sputnik V are among the non-replicating SARS-CoV-2 vaccines that are being mass-produced by relevant companies and they are currently injecting in many countries <bold>(</bold>
<xref rid="f0010" ref-type="fig">Fig. 2</xref>
<bold>).</bold>
<fig id="f0010" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Different types of SARS-CoV-2 vaccine candidates and immune response to vaccines.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig></p></sec><sec id="s0030"><label>3.3</label><title>DNA vaccines</title><p id="p0030">One of the reasons for the worsening of the infection in COVID-19 disease is the imbalance in the production of different immune cells, so that the increase of CD3<sup>+</sup> CD8<sup>+</sup> T cells is associated with the decrease of CD14<sup>+</sup> HLA-DR<sup>+</sup> monocytes <xref rid="bb0360" ref-type="bibr">[72]</xref>. Therefore, the point that is considered in the design of vaccines is to produce an effective immune response without creating such an imbalance. On the other hand, these designed vaccines are able to not only activate cellular immunity, but also activate humoral immune responses by producing immunogenic substances and releasing them from the cell and detected by B-cell receptors <xref rid="bb0365" ref-type="bibr">[73]</xref>. The first use of nucleic acids as a vaccine was about three decades ago, where DNA and RNA molecules expressing luciferase, chloramphenicol acetyltransferase, and beta-galactosidase genes were used to create immunogenicity in mouse. It was reported that the expression of these genes continued until two months after injection <xref rid="bb0370" ref-type="bibr">[74]</xref>. In general, DNA-based vaccines insert genes encoding an antigen into the host cells especially the antigen-presenting cells (APCs), using DNA plasmids as a vector. The mechanism of these vaccines is based on the principle that the genetic material delivered by them is located inside the cell nucleus. The mammalian promoter in the vector is then activated and transcription of the target genes is performed by the host cellular mechanism <xref rid="bb0375" ref-type="bibr">[75]</xref>, <xref rid="bb0380" ref-type="bibr">[76]</xref>. The method used to inject plasmid DNA into the cells is electroporation, which uses short electrical pulses to create temporarily and reversibly penetration into the cell membrane. This disruption of membrane allows large molecules such as plasmids to enter the cells. Using electroporation for plasmid injection can greatly increase the expression of the target protein <xref rid="bb0385" ref-type="bibr">[77]</xref>. The advantages of these vaccines are non-infectious, easy production in a short time, cost-effectiveness and stability. In addition, one of the benefits of DNA vaccines is greater thermal stability, so these vaccines have less refrigeration requirements than mRNA vaccines <xref rid="bb0390" ref-type="bibr">[78]</xref>. In COVID-19 disease, injection of a DNA vaccine (INO-4800) consisting of a plasmid containing a N-terminal Ig E leader sequence that encoded the S-protein of SARS-CoV-2 in guinea pigs and BALB/c mice produced neutralizing antibodies against SARS-CoV-2 <xref rid="bb0395" ref-type="bibr">[79]</xref>. Genexine Company, which has previously published the results of its Phase1/2 clinical trials using of electroporation for Human papillomavirus (HPV) vaccination, has conducted phase 1 and 2 clinical trials against SARS-CoV-2. Recent research by this company has shown that vaccines containing DNA encoding whole S-protein (pGX27-S) or S-protein without S2 fragment (pGX27-S &#916;TM), both induce the production of neutralizing antibodies, but pGX27-S &#916;TM vaccine induces a higher antibody titer <xref rid="bb0400" ref-type="bibr">[80]</xref>. Several DNA vaccines against COVID-19 are currently in various clinical trials stages and no complete information of the efficacy percent of these vaccines has been published so far <bold>(</bold>
<xref rid="t0005" ref-type="table">Table 1</xref>
<bold>)</bold>.</p></sec><sec id="s0035"><label>3.4</label><title>mRNA vaccines</title><p id="p0035">The mRNA-based vaccines contain mRNA molecules that encode protein antigens. New vaccine designs with the great technological innovation are constantly evolving to improve the stability of mRNA molecules and efficiency of protein translation, which improved immune response <xref rid="bb0405" ref-type="bibr">[81]</xref>. One way to overcome the instability of the mRNA is to place mRNA molecules inside lipid nanoparticles, which these nanoparticle delivery carriers also act as adjuvants and induce B-cell and T follicular helper immune response <xref rid="bb0410" ref-type="bibr">[82]</xref>, <xref rid="bb0415" ref-type="bibr">[83]</xref>. Codon optimization also reduces the degradation of mRNA molecules and increases the expression of coding antigens. In addition to, mRNA cap modification with synthesized anti-reverse cap analogs (ARCAs) increases translation efficiency and also leads to long-term protein expression and mRNA half-life in cells <xref rid="bb0420" ref-type="bibr">[84]</xref>, <xref rid="bb0425" ref-type="bibr">[85]</xref>, <xref rid="bb0430" ref-type="bibr">[86]</xref>. In this type of vaccine, the mRNA molecule is injected directly into the host cell and translated into the target protein in the cytoplasm. The overall design of mRNA vaccines contains an open reading frame (ORF) with a 3&#8242; poly-adenylated tail that can induce both cellular and humoral immune responses <xref rid="bb0435" ref-type="bibr">[87]</xref>. The mRNA-based vaccines have advantages over other vaccines: a) There is no risk of infection during vaccine production. b) Examination of mouse models has shown that repeated immunizations with mRNA-vaccines are associated with Long-term immunity in them. c) Since there is no require to enter the cell nucleus to the antigen expression, there is no possibility of insertional mutations creation in them <xref rid="bb0440" ref-type="bibr">[88]</xref>. So far, mRNA-based vaccine technology has been used to produce vaccines against various infectious diseases, including Ebola, respiratory syncytial virus, influenza virus, and HIV <xref rid="bb0405" ref-type="bibr">[81]</xref>, <xref rid="bb0445" ref-type="bibr">[89]</xref>, <xref rid="bb0450" ref-type="bibr">[90]</xref>. One of the main candidates for the SARS CoV-2 vaccine (mRNA-1273-based vaccine) have been developed with collaboration the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna. The mRNA-1273 molecule encodes the S2-protein antigen, which is made up of SARS-CoV-2 glycoprotein with the transmembrane anchor and an intact S1-S2 cleavage site <xref rid="bb0455" ref-type="bibr">[91]</xref>. This vaccine has gone through various approval stages and is now being used in most parts of the world. Pfizer and BioNTech have also developed several RNA-based vaccines that have been successful in clinical trials and are now being used in many countries <xref rid="bb0245" ref-type="bibr">[49]</xref>, <xref rid="bb0460" ref-type="bibr">[92]</xref>. These vaccines, like the Moderna vaccine, are embedded lipid nanoparticles (LNPs) and encode the membrane-anchored full-length S-protein (BNT162b2) and secreted receptor-binding-domain (BNT162b1) of SARS-CoV-2 <xref rid="bb0465" ref-type="bibr">[93]</xref>. BioNTech and Moderna vaccines also require booster doses to ensure high antibody titration and long-term safety. However, the response of the antibody to the receptor-binding domain in both vaccines showed a higher titer of antibody than in patients recovering from COVID-19 <xref rid="bb0455" ref-type="bibr">[91]</xref>, <xref rid="bb0470" ref-type="bibr">[94]</xref>. One of the points about these vaccines is that the injection of these vaccines in the first dose caused a mild headache, chills, fatigue, and myalgia and in the booster dose caused moderate to severe systemic or local reactions in some patients <xref rid="bb0455" ref-type="bibr">[91]</xref>, <xref rid="bb0460" ref-type="bibr">[92]</xref>, <xref rid="bb0475" ref-type="bibr">[95]</xref>. A major advantage of nucleic acid-based vaccines is the short time required from the design of these vaccines to clinical trials. Therefore, testing these vaccines against various likely mutations that occur in the SARS virus is easily and quickly possible <xref rid="bb0480" ref-type="bibr">[96]</xref>.</p></sec><sec id="s0040"><label>3.5</label><title>Protein subunit-based vaccines</title><p id="p0040">Another of the safe vaccines to fight SARS-CoV-2 are protein-based subunit vaccines. These vaccines are highly dependent on adjuvants to increase their immunogenicity. Peptides, like RNAs, are usually unstable and are therefore located within nanoparticles adsorbed onto adjuvants. Different S-protein subunits including RBD and RBD-Fc, and N-terminal domain of S-protein have shown different degrees of protection and immune responses in several animal models <xref rid="bb0485" ref-type="bibr">[97]</xref>, <xref rid="bb0490" ref-type="bibr">[98]</xref>, <xref rid="bb0495" ref-type="bibr">[99]</xref>, <xref rid="bb0500" ref-type="bibr">[100]</xref>. Process of preparing these vaccines is that the genes encoding the predominant antigenic components of the virus are cloned and expressed in various expression systems such as bacterial cells or mammalian cells, and then purified. These recombinant products are used to make stable vaccines <xref rid="bb0270" ref-type="bibr">[54]</xref>. In previous researches, S1 subunit vaccines for SARS-CoV produced from baculovirus <italic toggle="yes">Spodoptera frugiperda</italic> (Sf9) insect cell with saponin adjuvant showed a reduction in lung viral titer in young mice and using protollin adjuvant showed a reduction in lung viral titer in aged mice after injection <xref rid="bb0505" ref-type="bibr">[101]</xref>, <xref rid="bb0510" ref-type="bibr">[102]</xref>. Type of adjuvant can alter the effects of the vaccine, and sometimes the use of several adjuvants in combination can have synergistic effects on the level of immune response. For example, Lan et al. showed that the use of RBD subunit vaccine with alum and cysteine-phosphate-guanine (CpG) oligodeoxynucleotides (ODN) as the adjuvant against MERS-CoV induced much stronger humoral and cellular immune responses <xref rid="bb0500" ref-type="bibr">[100]</xref>. Several SARS-CoV-2 vaccine candidates, including a recombinant S-protein expressed in different cell lines, are currently being developed and used <xref rid="bb0515" ref-type="bibr">[103]</xref>. Among these candidates for the SARS-CoV-2 subunit vaccine, their leader is NVX-CoV2373, which is produced by Novavax and has gone through various stages of clinical trial (<xref rid="t0005" ref-type="table">Table 1</xref>). Production of this protein is done in the sf9 expression system of and the adjuvant used for it is Novavax's Matrix-M1 <xref rid="bb0250" ref-type="bibr">[50]</xref>, <xref rid="bb0520" ref-type="bibr">[104]</xref>. This vaccine contains a recombinant full-length spike glycoprotein that has been engineered to resist proteolytic degradation and has a high binding to ACE2 receptors <xref rid="bb0250" ref-type="bibr">[50]</xref>. Among the advantages of these vaccines are their safety and cost-effectiveness, and their limitations include the need for adjuvants in order to uptake of more protein into host antigen presenting cells and producing a long-term immune response <xref rid="bb0495" ref-type="bibr">[99]</xref>.</p></sec></sec><sec id="s0045"><label>4</label><title>SARS-CoV-2 vaccines challenges and considerations</title><p id="p0045">Despite the efforts of scientists and researchers around the world to advance the production of effective vaccines against SARS, there is still much to be discovered that can be used to improve the quality and effectiveness of vaccines and to overcome the limitations of current vaccines. One of the important points that impair the efficiency of COVID-19 vaccines is the occurrence of mutations in the genome sequence of SARS CoV-2 virus. Although the variety of mutations that have occurred so far is not very large, but the high transmission power and global spread of the virus can cause the phenomenon of natural selection to act on certain mutations <xref rid="bb0525" ref-type="bibr">[105]</xref>, <xref rid="bb0530" ref-type="bibr">[106]</xref>, <xref rid="bb0535" ref-type="bibr">[107]</xref>, <xref rid="bb0540" ref-type="bibr">[108]</xref>. Recognition of mutations in coding and non-coding sequences and genetic diversity of the virus is essential for the development of vaccines with long-term efficacy <xref rid="bb0105" ref-type="bibr">[21]</xref>, <xref rid="bb0545" ref-type="bibr">[109]</xref>. Another challenge for SARS CoV-2 vaccines is immunization programs and how to use the vaccines. Almost all available vaccine candidates have been delivered to recipients in clinical trials via intradermal or intramuscular route. The question is whether the antibodies produced in the blood reach the lungs and can work there. One method of vaccination that has been considered is mucosal vaccination, which may be effective in inducing an immune response in the mucosa and preventing the transmission of the virus to the respiratory tract and lungs <xref rid="bb0550" ref-type="bibr">[110]</xref>. In addition, each of these vaccine candidates has their own challenges and limitations, for example, previous immunity to adenoviruses is a concern for vaccines that use the virus as a carrier, as it may reduce the immune response <xref rid="bb0345" ref-type="bibr">[69]</xref>. Therefore, in the design of some of these vaccines using genetic engineering, an attempt has been made to use a modified chimpanzee-derived adenovirus <xref rid="bb0330" ref-type="bibr">[66]</xref>. In the case of mRNA-based vaccines, there is the problem of temperature-sensitive lipid nanoparticles containing mRNA and their limitations for production in large scale <xref rid="bb0460" ref-type="bibr">[92]</xref>. In DNA vaccines, the use of electroporation to deliver the vaccine to recipients increases the immune response, but this technology has made the use of these vaccines difficult and complicated <xref rid="bb0555" ref-type="bibr">[111]</xref>. There is also risk of vaccine-enhanced disease for inactivated vaccine candidates, specially vaccine-associated enhanced respiratory disease (VAERD), that needs to be considered <xref rid="bb0560" ref-type="bibr">[112]</xref>, <xref rid="bb0565" ref-type="bibr">[113]</xref>. Since antibody dependent enhancement (ADE) has always been a risk factor for vaccines of other coronaviruses, this should also be considered for the SARS CoV-2 vaccine candidates <xref rid="bb0570" ref-type="bibr">[114]</xref>. Although ADE phenomenon is more common in the case of <italic toggle="yes">Favivirus</italic> and some feline coronaviruses, if it occurs in the case of the SARS-CoV-2 vaccines, nucleic acid-based vaccines can quickly adopt solutions such as engineering or removing the motifs responsible for generating ADE from the vaccine antigen <xref rid="bb0575" ref-type="bibr">[115]</xref>, <xref rid="bb0580" ref-type="bibr">[116]</xref>. Given the re-infection observed in patients who had recovered from the COVID-19, this uncertainty about long-term protection for vaccines is also raised. Ideally, vaccines should provide long-term immunity, but based on experience with influenza vaccines, vaccination against SARS CoV-2 can be repeated annually <xref rid="bb0470" ref-type="bibr">[94]</xref>, <xref rid="bb0585" ref-type="bibr">[117]</xref>. Despite all the efforts and hopes for the vaccine, attention should not be diminished from trying to find effective drugs that reduce COVID-19 infection <xref rid="bb0570" ref-type="bibr">[114]</xref>. Another common concern about vaccines is that because vaccine candidates are tested on the certain numbers of a population in country of manufacture of the vaccine, it may have unknown effects when used globally that have not been seen in previous experiments. In addition, if not all population groups, including the elderly, young, special patients, and immunocompromised individuals, are not considered in the initial vaccine research, unwarranted side effects may occur during general and universal use of the vaccine in these groups <xref rid="bb0590" ref-type="bibr">[118]</xref>. The issue of political pressures to speed up the production process and approval of a vaccine may reduce the accuracy of the various stages of vaccine production, and ultimately make a vaccine available to the public with low efficacy or unexamined side effects <xref rid="bb0595" ref-type="bibr">[119]</xref>. In addition, if a vaccine receives the necessary approvals and reports a high percentage of efficacy in preclinical and clinical trials, but when used publicly in the population, it does not have the desired effect as expected, it erodes confidence in the vaccine. As a result, fewer people accept the vaccine, which will make the pandemic worse. Therefore, it is very important to build trust and establish effective communication between the people and the public health system and to provide transparent reports on vaccines <xref rid="bb0600" ref-type="bibr">[120]</xref>. One of the challenges of vaccination is the issue of inequality in the distribution and injection of vaccines. As this challenge has affected many people life around the world, especially in poor and less developed countries. In this regard, bollyky and bown chose the term &#8220;vaccine nationalism&#8221; to describe this tragedy <xref rid="bb0605" ref-type="bibr">[121]</xref>. Factors that have led some countries to turn to vaccine nationalism, stockpiling vaccines to prioritize rapid access to their citizenry, include intense public and political pressure and fears of declining immunity in their country <xref rid="bb0610" ref-type="bibr">[122]</xref>. Indeed, the bitter fact that developed countries continue to sign agreements with the world's largest pharmaceutical companies to purchase vaccines at prices that are not possible for most countries, and to buy and store vaccines more than their requirements, is a confirmation of the issue of vaccine nationalism. As a result, developing countries face acute problems in obtaining vaccines <xref rid="bb0615" ref-type="bibr">[123]</xref>, <xref rid="bb0620" ref-type="bibr">[124]</xref>, <xref rid="bb0625" ref-type="bibr">[125]</xref>. Raising the issue of vaccine nationalism once again exposed the bitter reality of the lives of the world's poor, who are constantly deprived of basic human rights, and justice in general. While the existence of these inequalities has raised concerns about the continuation of the COVID-19 pandemic, a series of short- and long-term reforms are underway to overcome this inequality. Due to this unfortunate fact, one of the concerns of some organizations such as the People's Vaccine Alliance, was that almost 70 lower-income countries would only be able to vaccinate 10% of their population, so COVAX, a part of a set of initiatives by the International Public Health Organization to accelerate the development and equitable distribution of health products, provided millions of doses of the vaccine for over 92 registered countries. However, these doses cannot fully cover the international need <xref rid="bb0605" ref-type="bibr">[121]</xref>.</p></sec><sec id="s0050"><label>5</label><title>Conclusion</title><p id="p0050">COVID-19 disease has been a serious threat to global health for more than sixteen months, and there is no definitive cure for it, and it is still associated with a high mortality rate worldwide. Researchers around the world have decided to develop effective vaccines to prevent the virus. To date, various vaccines have been produced with very high efficacy and are being used worldwide. Pfizer, BioNTech, Novavax, BBIBP-CorV, AstraZeneca, and Sputnik V vaccines with acceptable efficacy are including the most common vaccines against SARS CoV-2. Despite all this, there are still many ambiguities about vaccines. How long the immunity created by the vaccine lasts, whether the immunity developed after the infection is different from the immunity resulting from the vaccination, whether the general vaccination reduces the spread of the virus, do vaccines work the same in different populations and many other questions are still unanswered. In general, more studies are needed to determine the efficacy and safety of each vaccine, as well as the duration of immunization. While vaccines are now being given rapidly around the world, and many people hope to be able to return to normal life with these vaccines, even vaccine recipients are advised to follow the principles of preventing the transmission of the SARS CoV-2, including social distance and wearing a mask. With current evidences, all provided vaccines will help us to conquer this pandemic but developing general vaccines again all corona viruses and changes in study protocols to ease vaccine development in future pandemics are needed.</p></sec><sec sec-type="COI-statement"><title>Declaration of competing interest</title><p id="p0055">None to declare.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf202108140417465670"><person-group person-group-type="author"><name name-style="western"><surname>Ozma</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Maroufi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ganbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dal</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zeinalzadeh</surname><given-names>E.</given-names></name></person-group><article-title>Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period</article-title><source>Infez. Med.</source><volume>28</volume><issue>2</issue><year>2020</year><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">32275257</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf202108140425168529"><person-group person-group-type="author"><name name-style="western"><surname>Khodadadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Maroufi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ganbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Espsoito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zeinalzadeh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Study of combining virtual screening and antiviral treatments of the Sars-CoV-2 (Covid-19)</article-title><source>Microb. Pathog.</source><volume>145</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micpath.2020.104241</pub-id><pub-id pub-id-type="pmcid">PMC7199731</pub-id><pub-id pub-id-type="pmid">32387389</pub-id></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf202108140417525759"><person-group person-group-type="author"><name name-style="western"><surname>Najafi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maroufi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zeinalzadeh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ganbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Asgharzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>SARS-CoV-2 receptor ACE2 and molecular pathway to enter target cells during infection, reviews in medical</article-title><source>Microbiology</source><year>2020</year></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf202108140344519681"><person-group person-group-type="author"><name name-style="western"><surname>Abd El-Aziz</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Stockand</surname><given-names>J.D.</given-names></name></person-group><article-title>Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status</article-title><source>Infect. Genet. Evol.</source><volume>83</volume><year>2020</year><object-id pub-id-type="publisher-id">104327</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.meegid.2020.104327</pub-id><pub-id pub-id-type="pmcid">PMC7166307</pub-id><pub-id pub-id-type="pmid">32320825</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf202108140440401479"><person-group person-group-type="author"><name name-style="western"><surname>Fathizadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taghizadeh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Safari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Khiabani</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Babak</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hamzavi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ganbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zeinalzadeh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Study presence of COVID-19 (SARS-CoV-2) in the sweat of patients infected with Covid-19</article-title><source>Microb. Pathog.</source><volume>149</volume><year>2020</year><fpage>104556</fpage><pub-id pub-id-type="pmid">33031898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micpath.2020.104556</pub-id><pub-id pub-id-type="pmcid">PMC7534876</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf202108140345059961"><person-group person-group-type="author"><name name-style="western"><surname>Randolph</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name></person-group><article-title>Herd immunity: understanding COVID-19</article-title><source>Immunity</source><volume>52</volume><issue>5</issue><year>2020</year><fpage>737</fpage><lpage>741</lpage><pub-id pub-id-type="pmid">32433946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2020.04.012</pub-id><pub-id pub-id-type="pmcid">PMC7236739</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf202108140417542237"><person-group person-group-type="author"><name name-style="western"><surname>Fathizadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Maroufi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Momen-Heravi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Espsoito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Protection and disinfection policies against SARS-CoV-2 (COVID-19)</article-title><source>Infez. Med.</source><volume>28</volume><issue>2</issue><year>2020</year><fpage>185</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">32275260</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf202108140345070619"><person-group person-group-type="author"><name name-style="western"><surname>Gholizadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Safari</surname><given-names>R.</given-names></name><name name-style="western"><surname>Marofi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zeinalzadeh</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pagliano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ganbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Khodadadi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yousefi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Alteration of liver biomarkers in patients with SARS-CoV-2 (COVID-19)</article-title><source>J. Inflamm. Res.</source><volume>13</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/JIR.S257078</pub-id><pub-id pub-id-type="pmcid">PMC7335895</pub-id><pub-id pub-id-type="pmid">32669866</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf202108140422388303"><person-group person-group-type="author"><name name-style="western"><surname>Spychalski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Blazynska-Spychalska</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kobiela</surname><given-names>J.</given-names></name></person-group><article-title>Estimating case fatality rates of COVID-19</article-title><source>Lancet Infect. Dis.</source><volume>20</volume><issue>7</issue><year>2020</year><fpage>774</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">32243815</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30246-2</pub-id><pub-id pub-id-type="pmcid">PMC7270730</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf202108140345085645"><person-group person-group-type="author"><name name-style="western"><surname>Gholizadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sanogo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oumarou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Cissoko</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sow</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Pagliano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Akouda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soufiane</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Iknane</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Oury</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Fighting COVID-19 in West Africa after experiencing the Ebola epidemic</article-title><source>Health Promot. Perspect.</source><volume>11</volume><issue>1</issue><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.34172/hpp.2021.02</pub-id><pub-id pub-id-type="pmcid">PMC7967127</pub-id><pub-id pub-id-type="pmid">33758750</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf202108140420029749"><person-group person-group-type="author"><name name-style="western"><surname>Ahmadian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fathizadeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khiabani</surname><given-names>S.Shabestari</given-names></name><name name-style="western"><surname>Asgharzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>COVID-19 reinfection in a healthcare worker after exposure with high dose of virus: a case report</article-title><comment>Jun 23</comment><source>Clin. Case Rep.</source><volume>9</volume><issue>6</issue><year>2021</year><object-id pub-id-type="publisher-id">e04257</object-id><pub-id pub-id-type="doi">10.1002/ccr3</pub-id><comment>4257 eCollection 2021 Jun</comment><pub-id pub-id-type="pmcid">PMC8222657</pub-id><pub-id pub-id-type="pmid">34194783</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf202108140422460635"><person-group person-group-type="author"><name name-style="western"><surname>Narenji</surname><given-names>H.</given-names></name><name name-style="western"><surname>Gholizadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aghazadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rezaee</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Asgharzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Peptide nucleic acids (PNAs): currently potential bactericidal agents</article-title><source>Biomed. Pharmacother.</source><volume>93</volume><year>2017</year><fpage>580</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">28686972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.06.092</pub-id></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf202108140345085742"><person-group person-group-type="author"><name name-style="western"><surname>Alihosseini</surname><given-names>S.</given-names></name><name name-style="western"><surname>Leylabadlo</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Parsaei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sarafraz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghanbarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Esposito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Current drugs with potential for COVID-19 therapy: a literature review</article-title><source>Rev. Med. Microbiol.</source><year>2021</year></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf202108140422504693"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>G.</given-names></name><name name-style="western"><surname>De Clercq</surname><given-names>E.</given-names></name></person-group><article-title>Therapeutic options for the 2019 novel coronavirus (2019-nCoV)</article-title><source>Nat. Rev. Drug Discov.</source><volume>19</volume><issue>3</issue><year>2020</year><fpage>149</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">32127666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41573-020-00016-0</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf202108140420050249"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>F.</given-names></name><name name-style="western"><surname>Krieger</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hufert</surname><given-names>F.</given-names></name><name name-style="western"><surname>K&#252;pper</surname><given-names>J.-H.</given-names></name></person-group><article-title>Herd immunity or suppression strategy to combat COVID-19</article-title><source>Clin. Hemorheol. Microcirc.</source><year>2020</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.3233/CH-209006</pub-id><pub-id pub-id-type="pmcid">PMC7458501</pub-id><pub-id pub-id-type="pmid">32538831</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf202108140423216187"><person-group person-group-type="author"><name name-style="western"><surname>Calina</surname><given-names>D.</given-names></name><name name-style="western"><surname>Docea</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Petrakis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Egorov</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ishmukhametov</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Gabibov</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Shtilman</surname><given-names>M.I.</given-names></name><name name-style="western"><surname>Kostoff</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F.</given-names></name><name name-style="western"><surname>Vinceti</surname><given-names>M.</given-names></name></person-group><article-title>Towards effective COVID-19 vaccines: updates, perspectives and challenges</article-title><source>Int. J. Mol. Med.</source><volume>46</volume><issue>1</issue><year>2020</year><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">32377694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3892/ijmm.2020.4596</pub-id><pub-id pub-id-type="pmcid">PMC7255458</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf202108140422568913"><person-group person-group-type="author"><name name-style="western"><surname>Sempowski</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>K.O.</given-names></name><name name-style="western"><surname>Acharya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wiehe</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>B.F.</given-names></name></person-group><article-title>Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19</article-title><source>Cell.</source><volume>181</volume><year>2020</year><fpage>1458</fpage><lpage>1463</lpage><pub-id pub-id-type="pmid">32492407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.05.041</pub-id><pub-id pub-id-type="pmcid">PMC7250787</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf202108140423111108"><person-group person-group-type="author"><name name-style="western"><surname>Shereen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kazmi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>N.</given-names></name><name name-style="western"><surname>Siddique</surname><given-names>R.</given-names></name></person-group><article-title>COVID-19 infection: origin, transmission, and characteristics of human coronaviruses</article-title><source>J. Adv. Res.</source><volume>24</volume><year>2020</year><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">32257431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jare.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7113610</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf202108140345090482"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>P.</given-names></name><name name-style="western"><surname>Mi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>J.</given-names></name></person-group><article-title>Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">32221306</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-15562-9</pub-id><pub-id pub-id-type="pmcid">PMC7100515</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf202108140345103685"><person-group person-group-type="author"><name name-style="western"><surname>Tse</surname><given-names>L.V.</given-names></name><name name-style="western"><surname>Meganck</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>The current and future state of vaccines, antivirals and gene therapies against emerging coronaviruses</article-title><source>Front. Microbiol.</source><volume>11</volume><year>2020</year><fpage>658</fpage><pub-id pub-id-type="pmid">32390971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2020.00658</pub-id><pub-id pub-id-type="pmcid">PMC7193113</pub-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf202108140420154599"><person-group person-group-type="author"><name name-style="western"><surname>Naqvi</surname><given-names>A.A.T.</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mohammad</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>U.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atif</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Hariprasad</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Hassan</surname><given-names>M.I.</given-names></name></person-group><article-title>Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach</article-title><source>Biochim. Biophys. Acta (BBA)-Mol. Basis Dis.</source><volume>1866</volume><issue>10</issue><year>2020</year><object-id pub-id-type="publisher-id">165878</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbadis.2020.165878</pub-id><pub-id pub-id-type="pmcid">PMC7293463</pub-id><pub-id pub-id-type="pmid">32544429</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf202108140423121208"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>Advances in research on ACE2 as a receptor for 2019-nCoV</article-title><source>Cell. Mol. Life Sci.</source><volume>78</volume><issue>2</issue><year>2021</year><fpage>531</fpage><lpage>544</lpage><pub-id pub-id-type="pmid">32780149</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-020-03611-x</pub-id><pub-id pub-id-type="pmcid">PMC7417784</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf202108140423122528"><person-group person-group-type="author"><name name-style="western"><surname>Boehm</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>E.G.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2&#8212;a new cardiac regulator</article-title><source>N. Engl. J. Med.</source><volume>347</volume><issue>22</issue><year>2002</year><fpage>1795</fpage><lpage>1797</lpage><pub-id pub-id-type="pmid">12456857</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMcibr022472</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf202108140345110310"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Balaji</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>J.</given-names></name></person-group><article-title>Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19</article-title><source>Mol. Biol. Rep.</source><volume>1</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11033-020-05478-4</pub-id><pub-id pub-id-type="pmcid">PMC7224351</pub-id><pub-id pub-id-type="pmid">32410141</pub-id></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf202108140420185467"><person-group person-group-type="author"><name name-style="western"><surname>Hamming</surname><given-names>I.</given-names></name><name name-style="western"><surname>Timens</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bulthuis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lely</surname><given-names>A.</given-names></name><name name-style="western"><surname>G.v. Navis</surname><given-names>H.van Goor</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J. Pathol.</source><volume>203</volume><issue>2</issue><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15141377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/path.1570</pub-id><pub-id pub-id-type="pmcid">PMC7167720</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf202108140345106425"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Han</surname><given-names>Z.</given-names></name></person-group><article-title>Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection</article-title><source>Front. Med.</source><year>2020</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11684-020-0754-0</pub-id><pub-id pub-id-type="pmcid">PMC7088738</pub-id><pub-id pub-id-type="pmid">32170560</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf202108140345112831"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>T.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W.</given-names></name></person-group><article-title>The digestive system is a potential route of 2019-nCov infection: a bioinformatics analysis based on single-cell transcriptomes</article-title><source>BioRxiv</source><year>2020</year></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf202108140345138287"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>W.</given-names></name></person-group><article-title>Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov</article-title><source>BioRxiv</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1164/rccm.202001-0179LE</pub-id><pub-id pub-id-type="pmcid">PMC7462411</pub-id><pub-id pub-id-type="pmid">32663409</pub-id></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf202108140345154709"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title><source>Cell Res.</source><volume>30</volume><issue>4</issue><year>2020</year><fpage>343</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">32231345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41422-020-0305-x</pub-id><pub-id pub-id-type="pmcid">PMC7104723</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf202108140343024746"><person-group person-group-type="author"><name name-style="western"><surname>South</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tomlinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edmonston</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hiremath</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sparks</surname><given-names>M.A.</given-names></name></person-group><article-title>Controversies of renin&#8211;angiotensin system inhibition during the COVID-19 pandemic</article-title><source>Nat. Rev. Nephrol.</source><volume>16</volume><issue>6</issue><year>2020</year><fpage>305</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">32246101</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41581-020-0279-4</pub-id><pub-id pub-id-type="pmcid">PMC7118703</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf202108140342492829"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Rambaut</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lipkin</surname><given-names>W.I.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Garry</surname><given-names>R.F.</given-names></name></person-group><article-title>The proximal origin of SARS-CoV-2</article-title><source>Nat. Med.</source><volume>26</volume><issue>4</issue><year>2020</year><fpage>450</fpage><lpage>452</lpage><pub-id pub-id-type="pmid">32284615</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0820-9</pub-id><pub-id pub-id-type="pmcid">PMC7095063</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf202108140342254519"><person-group person-group-type="author"><name name-style="western"><surname>Ou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Dominguez</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Holmes</surname><given-names>K.V.</given-names></name><name name-style="western"><surname>Qian</surname><given-names>Z.</given-names></name></person-group><article-title>Identification of the fusion peptide-containing region in betacoronavirus spike glycoproteins</article-title><source>J. Virol.</source><volume>90</volume><issue>12</issue><year>2016</year><fpage>5586</fpage><lpage>5600</lpage><pub-id pub-id-type="pmid">27030273</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00015-16</pub-id><pub-id pub-id-type="pmcid">PMC4886789</pub-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf202108140345171313"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.-J.</given-names></name></person-group><article-title>Development of subunit vaccines against severe acute respiratory syndrome</article-title><source>Drugs Today</source><volume>44</volume><issue>1</issue><year>2008</year><fpage>63</fpage><lpage>74</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1358/dot.2008.44.1.1131830</pub-id><pub-id pub-id-type="pmid">18301805</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf202108140342278034"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Paddock</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Cellular immune responses to severe acute respiratory syndrome coronavirus (SARS-CoV) infection in senescent BALB/c mice: CD4 T cells are important in control of SARS-CoV infection</article-title><source>J. Virol.</source><volume>84</volume><issue>3</issue><year>2010</year><fpage>1289</fpage><lpage>1301</lpage><pub-id pub-id-type="pmid">19906920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01281-09</pub-id><pub-id pub-id-type="pmcid">PMC2812346</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf202108140345178221"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Aikins</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Non-viral COVID-19 vaccine delivery systems</article-title><source>Adv. Drug Deliv. Rev.</source><volume>169</volume><year>2020</year><fpage>137</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">33340620</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.12.008</pub-id><pub-id pub-id-type="pmcid">PMC7744276</pub-id></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf202108140343067497"><person-group person-group-type="author"><name name-style="western"><surname>Michen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Graule</surname><given-names>T.</given-names></name></person-group><article-title>Isoelectric points of viruses</article-title><source>J. Appl. Microbiol.</source><volume>109</volume><issue>2</issue><year>2010</year><fpage>388</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">20102425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2672.2010.04663.x</pub-id></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf202108140421058416"><person-group person-group-type="author"><name name-style="western"><surname>Gasteiger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Gattiker</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hoogland</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ivanyi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Appel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bairoch</surname><given-names>A.</given-names></name></person-group><article-title>ExPASy: the proteomics server for in-depth protein knowledge and analysis</article-title><source>Nucleic Acids Res.</source><volume>31</volume><year>2003</year><fpage>3784</fpage><lpage>3788</lpage><pub-id pub-id-type="pmid">12824418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkg563</pub-id><pub-id pub-id-type="pmcid">PMC168970</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf202108140343087165"><source>Nucleic Acids Res.</source><volume>49</volume><issue>D1</issue><year>2021</year><fpage>D480</fpage><lpage>D489</lpage><pub-id pub-id-type="pmid">33237286</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkaa1100</pub-id><pub-id pub-id-type="pmcid">PMC7778908</pub-id></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="book" id="rf202108140421090046"><person-group person-group-type="author"><name name-style="western"><surname>Shahid</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ashfaq</surname><given-names>U.A.</given-names></name><name name-style="western"><surname>Aslam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>I.</given-names></name><name name-style="western"><surname>Fareed</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zohaib</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Qamar</surname><given-names>M.T.u.</given-names></name></person-group><part-title>Structural Modeling and Conserved Epitopes Prediction Against SARS-COV-2 Structural Proteins for Vaccine Development</part-title><year>2020</year></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="book" id="rf202108140421225540"><person-group person-group-type="author"><name name-style="western"><surname>Rehman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashfaq</surname><given-names>U.</given-names></name><name name-style="western"><surname>Awan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fatima</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shahid</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name></person-group><part-title>Designing of a Next Generation Multiepitope Based Vaccine (MEV) Against SARS-COV-2: Immunoinformatics and in Silicoapproaches</part-title><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0244176</pub-id><pub-id pub-id-type="pmcid">PMC7755200</pub-id><pub-id pub-id-type="pmid">33351863</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf202108140424293109"><person-group person-group-type="author"><name name-style="western"><surname>Chin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Perera</surname><given-names>M.</given-names></name></person-group><article-title>Correspondence. Stability of SARS-CoV-2 in different environmental conditions</article-title><source>Lancet Microbe</source><volume>1</volume><issue>10</issue><year>2020</year><object-id pub-id-type="publisher-id">30003-3</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2666-5247(20)30003-3</pub-id><pub-id pub-id-type="pmcid">PMC7214863</pub-id><pub-id pub-id-type="pmid">32835322</pub-id></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="book" id="rf202108140414261314"><person-group person-group-type="author"><name name-style="western"><surname>Kapil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oberst</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bieker</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>C.V.</given-names></name></person-group><part-title>Rapid Inactivation of SARS-like Coronaviruses</part-title><year>2004</year><publisher-name>Sandia National Laboratories</publisher-name></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="book" id="rf202108140414331506"><person-group person-group-type="author"><name name-style="western"><surname>Block</surname><given-names>S.S.</given-names></name></person-group><part-title>Disinfection, Sterilization, and Preservation</part-title><year>2001</year><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf202108140414367363"><person-group person-group-type="author"><name name-style="western"><surname>Delrue</surname><given-names>I.</given-names></name><name name-style="western"><surname>Verzele</surname><given-names>D.</given-names></name><name name-style="western"><surname>Madder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nauwynck</surname><given-names>H.J.</given-names></name></person-group><article-title>Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges</article-title><source>Expert Rev. Vaccines</source><volume>11</volume><issue>6</issue><year>2012</year><fpage>695</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">22873127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/erv.12.38</pub-id></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf202108140414404898"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koen</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Padayachee</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Dheda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barnabas</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.E.</given-names></name></person-group><article-title>Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B. 1.351 variant</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>1885</fpage><lpage>1898</lpage><pub-id pub-id-type="pmid">33725432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102214</pub-id><pub-id pub-id-type="pmcid">PMC7993410</pub-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf202108140414445250"><person-group person-group-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Owens</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Babbage</surname><given-names>G.</given-names></name></person-group><article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial</article-title><source>Lancet</source><volume>396</volume><issue>10267</issue><year>2020</year><fpage>1979</fpage><lpage>1993</lpage><pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf202108140414460355"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name></person-group><article-title>Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials</article-title><source>JAMA</source><volume>324</volume><issue>10</issue><year>2020</year><fpage>951</fpage><lpage>960</lpage><pub-id pub-id-type="pmid">32789505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.15543</pub-id><pub-id pub-id-type="pmcid">PMC7426884</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf202108140414464880"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18&#8211;59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect. Dis.</source><volume>21</volume><issue>2</issue><year>2021</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf202108140414485405"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>P&#233;rez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>C.</given-names></name></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><issue>27</issue><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf202108140414533310"><person-group person-group-type="author"><name name-style="western"><surname>Keech</surname><given-names>C.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>I.</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>P.</given-names></name><name name-style="western"><surname>Neal</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plested</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cloney-Clark</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H.</given-names></name></person-group><article-title>Phase 1&#8211;2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine</article-title><source>N. Engl. J. Med.</source><volume>383</volume><issue>24</issue><year>2020</year><fpage>2320</fpage><lpage>2332</lpage><pub-id pub-id-type="pmid">32877576</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2026920</pub-id><pub-id pub-id-type="pmcid">PMC7494251</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf202108140343071424"><person-group person-group-type="author"><name name-style="western"><surname>Barberis</surname><given-names>I.</given-names></name><name name-style="western"><surname>Myles</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ault</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bragazzi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Martini</surname><given-names>M.</given-names></name></person-group><article-title>History and evolution of influenza control through vaccination: from the first monovalent vaccine to universal vaccines</article-title><source>J. Prev. Med. Hyg.</source><volume>57</volume><issue>3</issue><year>2016</year><fpage>E115</fpage><pub-id pub-id-type="pmid">27980374</pub-id><pub-id pub-id-type="pmcid">PMC5139605</pub-id></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf202108140414562667"><person-group person-group-type="author"><name name-style="western"><surname>Moghaddam</surname><given-names>A.</given-names></name><name name-style="western"><surname>Olszewska</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tregoning</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Helson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sattentau</surname><given-names>Q.J.</given-names></name><name name-style="western"><surname>Openshaw</surname><given-names>P.J.</given-names></name></person-group><article-title>A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines</article-title><source>Nat. Med.</source><volume>12</volume><issue>8</issue><year>2006</year><fpage>905</fpage><lpage>907</lpage><pub-id pub-id-type="pmid">16862151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm1456</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf202108140414557967"><person-group person-group-type="author"><name name-style="western"><surname>Darnell</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Feinstone</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.R.</given-names></name></person-group><article-title>Inactivation of the coronavirus that induces severe acute respiratory syndrome,SARS-CoV</article-title><source>J. Virol. Methods</source><volume>121</volume><issue>1</issue><year>2004</year><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">15350737</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jviromet.2004.06.006</pub-id><pub-id pub-id-type="pmcid">PMC7112912</pub-id></element-citation></ref><ref id="bb0270"><label>54</label><element-citation publication-type="journal" id="rf202108140414571932"><person-group person-group-type="author"><name name-style="western"><surname>Nascimento</surname><given-names>I.</given-names></name><name name-style="western"><surname>Leite</surname><given-names>L.</given-names></name></person-group><article-title>Recombinant vaccines and the development of new vaccine strategies</article-title><source>Braz. J. Med. Biol. Res.</source><volume>45</volume><issue>12</issue><year>2012</year><fpage>1102</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">22948379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1590/S0100-879X2012007500142</pub-id><pub-id pub-id-type="pmcid">PMC3854212</pub-id></element-citation></ref><ref id="bb0275"><label>55</label><element-citation publication-type="journal" id="rf202108140414577131"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Meldgaard</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name></person-group><article-title>Novel platforms for the development of a universal influenza vaccine</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>600</fpage><pub-id pub-id-type="pmid">29628926</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.00600</pub-id><pub-id pub-id-type="pmcid">PMC5877485</pub-id></element-citation></ref><ref id="bb0280"><label>56</label><element-citation publication-type="journal" id="rf202108140415010300"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>Z.</given-names></name></person-group><article-title>Development of an inactivated vaccine candidate for SARS-CoV-2</article-title><source>Science</source><volume>369</volume><issue>6499</issue><year>2020</year><fpage>77</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">32376603</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id></element-citation></ref><ref id="bb0285"><label>57</label><element-citation publication-type="journal" id="rf202108140415006620"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect. Dis.</source><volume>21</volume><issue>1</issue><year>2021</year><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="bb0290"><label>58</label><element-citation publication-type="journal" id="rf202108140343114566"><person-group person-group-type="author"><name name-style="western"><surname>Fulginiti</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Eller</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Downie</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Kempe</surname><given-names>C.H.</given-names></name></person-group><article-title>Altered reactivity to measles virus: atypical measles in children previously immunized with inactivated measles virus vaccines</article-title><source>JAMA</source><volume>202</volume><issue>12</issue><year>1967</year><fpage>1075</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">6072745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.202.12.1075</pub-id></element-citation></ref><ref id="bb0295"><label>59</label><element-citation publication-type="journal" id="rf202108140343114712"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W.-C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.-H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>J.H.</given-names></name></person-group><article-title>Disappearance of antibodies to SARS-associated coronavirus after recovery</article-title><source>N. Engl. J. Med.</source><volume>357</volume><issue>11</issue><year>2007</year><fpage>1162</fpage><lpage>1163</lpage><pub-id pub-id-type="pmid">17855683</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc070348</pub-id></element-citation></ref><ref id="bb0300"><label>60</label><element-citation publication-type="journal" id="rf202108140343139171"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Symons</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Berg</surname><given-names>P.</given-names></name></person-group><article-title>Biochemical method for inserting new genetic information into DNA of simian virus 40: circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli</article-title><source>Proc. Natl. Acad. Sci.</source><volume>69</volume><issue>10</issue><year>1972</year><fpage>2904</fpage><lpage>2909</lpage><pub-id pub-id-type="pmid">4342968</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.69.10.2904</pub-id><pub-id pub-id-type="pmcid">PMC389671</pub-id></element-citation></ref><ref id="bb0305"><label>61</label><element-citation publication-type="journal" id="rf202108140343180450"><person-group person-group-type="author"><name name-style="western"><surname>Mackett</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group><article-title>Vaccinia virus: a selectable eukaryotic cloning and expression vector</article-title><source>Proc. Natl. Acad. Sci.</source><volume>79</volume><issue>23</issue><year>1982</year><fpage>7415</fpage><lpage>7419</lpage><pub-id pub-id-type="pmid">6296831</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.79.23.7415</pub-id><pub-id pub-id-type="pmcid">PMC347350</pub-id></element-citation></ref><ref id="bb0310"><label>62</label><element-citation publication-type="journal" id="rf202108140344023112"><person-group person-group-type="author"><name name-style="western"><surname>Benihoud</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Perricaudet</surname><given-names>M.</given-names></name></person-group><article-title>Adenovirus vectors for gene delivery</article-title><source>Curr. Opin. Biotechnol.</source><volume>10</volume><issue>5</issue><year>1999</year><fpage>440</fpage><lpage>447</lpage><pub-id pub-id-type="pmid">10508634</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0958-1669(99)00007-5</pub-id></element-citation></ref><ref id="bb0315"><label>63</label><element-citation publication-type="journal" id="rf202108140345203621"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Hung</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus</article-title><source>Immunology</source><volume>145</volume><issue>4</issue><year>2015</year><fpage>476</fpage><lpage>484</lpage><pub-id pub-id-type="pmid">25762305</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.12462</pub-id><pub-id pub-id-type="pmcid">PMC4515128</pub-id></element-citation></ref><ref id="bb0320"><label>64</label><element-citation publication-type="journal" id="rf202108140415014905"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>K.Q.</given-names></name><name name-style="western"><surname>Yoshizaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yashima</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mizuguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name></person-group><article-title>Designed recombinant adenovirus type 5 vector induced envelope-specific CD8 cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1</article-title><source>J. Gene Med.</source><volume>11</volume><issue>2</issue><year>2009</year><fpage>139</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">19065543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.1277</pub-id></element-citation></ref><ref id="bb0325"><label>65</label><element-citation publication-type="journal" id="rf202108140415014885"><person-group person-group-type="author"><name name-style="western"><surname>Abe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kondo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yoshizaki</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mizuguchi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name></person-group><article-title>Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5</article-title><source>J. Gene Med.</source><volume>11</volume><issue>7</issue><year>2009</year><fpage>570</fpage><lpage>579</lpage><pub-id pub-id-type="pmid">19391169</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jgm.1332</pub-id><pub-id pub-id-type="pmcid">PMC7385988</pub-id></element-citation></ref><ref id="bb0330"><label>66</label><element-citation publication-type="journal" id="rf202108140415037152"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bittaye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clutterbuck</surname><given-names>E.A.</given-names></name></person-group><article-title>Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial</article-title><source>Lancet</source><volume>396</volume><issue>10249</issue><year>2020</year><fpage>467</fpage><lpage>478</lpage><pub-id pub-id-type="pmid">32702298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31604-4</pub-id><pub-id pub-id-type="pmcid">PMC7445431</pub-id></element-citation></ref><ref id="bb0335"><label>67</label><element-citation publication-type="journal" id="rf202108140415031369"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bergelson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ertl</surname><given-names>H.C.</given-names></name></person-group><article-title>Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product</article-title><source>J. Virol.</source><volume>76</volume><issue>6</issue><year>2002</year><fpage>2667</fpage><lpage>2675</lpage><pub-id pub-id-type="pmid">11861833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.76.6.2667-2675.2002</pub-id><pub-id pub-id-type="pmcid">PMC135983</pub-id></element-citation></ref><ref id="bb0340"><label>68</label><element-citation publication-type="journal" id="rf202108140343118978"><person-group person-group-type="author"><name name-style="western"><surname>Sekaly</surname><given-names>R.-P.</given-names></name></person-group><article-title>The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?</article-title><source>J. Exp. Med.</source><volume>205</volume><issue>1</issue><year>2008</year><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">18195078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20072681</pub-id><pub-id pub-id-type="pmcid">PMC2234358</pub-id></element-citation></ref><ref id="bb0345"><label>69</label><element-citation publication-type="journal" id="rf202108140415033481"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.-C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.-Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.-H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.-F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-J.</given-names></name></person-group><article-title>Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet</source><volume>396</volume><issue>10249</issue><year>2020</year><fpage>479</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">32702299</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31605-6</pub-id><pub-id pub-id-type="pmcid">PMC7836858</pub-id></element-citation></ref><ref id="bb0350"><label>70</label><element-citation publication-type="journal" id="rf202108140415056360"><person-group person-group-type="author"><name name-style="western"><surname>Geisbert</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>L.</given-names></name><name name-style="western"><surname>Asiedu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honko</surname><given-names>A.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mulangu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pau</surname><given-names>M.G.</given-names></name></person-group><article-title>Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge</article-title><source>J. Virol.</source><volume>85</volume><issue>9</issue><year>2011</year><fpage>4222</fpage><lpage>4233</lpage><pub-id pub-id-type="pmid">21325402</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02407-10</pub-id><pub-id pub-id-type="pmcid">PMC3126236</pub-id></element-citation></ref><ref id="bb0355"><label>71</label><element-citation publication-type="journal" id="rf202108140415078794"><person-group person-group-type="author"><name name-style="western"><surname>Dicks</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Wadell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bojang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gilbert</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Cottingham</surname><given-names>M.G.</given-names></name></person-group><article-title>A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity</article-title><source>PloS one</source><volume>7</volume><issue>7</issue><year>2012</year><object-id pub-id-type="publisher-id">e40385</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0040385</pub-id><pub-id pub-id-type="pmcid">PMC3396660</pub-id><pub-id pub-id-type="pmid">22808149</pub-id></element-citation></ref><ref id="bb0360"><label>72</label><element-citation publication-type="journal" id="rf202108140415067579"><person-group person-group-type="author"><name name-style="western"><surname>Duerr</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heine</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hamiko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Luetkens</surname><given-names>J.</given-names></name><name name-style="western"><surname>Nattermann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rieke</surname><given-names>G.</given-names></name><name name-style="western"><surname>Isaak</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jehle</surname><given-names>J.</given-names></name><name name-style="western"><surname>Held</surname><given-names>S.</given-names></name></person-group><article-title>Parameters predicting COVID-19-induced myocardial injury and mortality</article-title><source>Life Sci.</source><volume>260</volume><year>2020</year><object-id pub-id-type="publisher-id">118400</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118400</pub-id><pub-id pub-id-type="pmcid">PMC7480277</pub-id><pub-id pub-id-type="pmid">32918975</pub-id></element-citation></ref><ref id="bb0365"><label>73</label><element-citation publication-type="journal" id="rf202108140415078951"><person-group person-group-type="author"><name name-style="western"><surname>Batty</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Bachelder</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Ainslie</surname><given-names>K.M.</given-names></name></person-group><article-title>Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection</article-title><source>Adv. Drug Deliv. Rev.</source><volume>169</volume><year>2020</year><fpage>168</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">33316346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addr.2020.12.006</pub-id><pub-id pub-id-type="pmcid">PMC7733686</pub-id></element-citation></ref><ref id="bb0370"><label>74</label><element-citation publication-type="journal" id="rf202108140343117232"><person-group person-group-type="author"><name name-style="western"><surname>Wolff</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Acsadi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Felgner</surname><given-names>P.L.</given-names></name></person-group><article-title>Direct gene transfer into mouse muscle in vivo</article-title><source>Science</source><volume>247</volume><issue>4949</issue><year>1990</year><fpage>1465</fpage><lpage>1468</lpage><pub-id pub-id-type="pmid">1690918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.1690918</pub-id></element-citation></ref><ref id="bb0375"><label>75</label><element-citation publication-type="journal" id="rf202108140415084260"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>L.Y.Y.</given-names></name><name name-style="western"><surname>Izzard</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hurt</surname><given-names>A.C.</given-names></name></person-group><article-title>A review of DNA vaccines against influenza</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1568</fpage><pub-id pub-id-type="pmid">30038621</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01568</pub-id><pub-id pub-id-type="pmcid">PMC6046547</pub-id></element-citation></ref><ref id="bb0380"><label>76</label><element-citation publication-type="journal" id="rf202108140415117902"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Molecular mechanisms for enhanced DNA vaccine immunogenicity</article-title><source>Expert Rev. Vaccines</source><volume>15</volume><issue>3</issue><year>2016</year><fpage>313</fpage><lpage>329</lpage><pub-id pub-id-type="pmid">26707950</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2016.1124762</pub-id><pub-id pub-id-type="pmcid">PMC4955855</pub-id></element-citation></ref><ref id="bb0385"><label>77</label><element-citation publication-type="journal" id="rf202108140415110664"><person-group person-group-type="author"><name name-style="western"><surname>Dupuis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Denis-Mize</surname><given-names>K.</given-names></name><name name-style="western"><surname>Woo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Goldbeck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Selby</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Otten</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Donnelly</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>G.</given-names></name></person-group><article-title>Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice</article-title><source>J. Immunol.</source><volume>165</volume><issue>5</issue><year>2000</year><fpage>2850</fpage><lpage>2858</lpage><pub-id pub-id-type="pmid">10946318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.165.5.2850</pub-id></element-citation></ref><ref id="bb0390"><label>78</label><element-citation publication-type="journal" id="rf202108140343123125"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Jacob</surname><given-names>J.</given-names></name></person-group><article-title>DNA vaccines against influenza viruses</article-title><source>Vaccines Pandemic Influenza</source><year>2009</year><fpage>197</fpage><lpage>210</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-540-92165-3_10</pub-id><pub-id pub-id-type="pmid">19768407</pub-id></element-citation></ref><ref id="bb0395"><label>79</label><element-citation publication-type="journal" id="rf202108140453139271"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gary</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Purwar</surname><given-names>M.</given-names></name></person-group><article-title>Immunogenicity of a DNA vaccine candidate for COVID-19</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></element-citation></ref><ref id="bb0400"><label>80</label><element-citation publication-type="journal" id="rf202108140415129332"><person-group person-group-type="author"><name name-style="western"><surname>Seo</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Suh</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>J.I.</given-names></name><name name-style="western"><surname>Jang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Koo</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>S.-H.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Song</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.-J.</given-names></name></person-group><article-title>Soluble spike DNA vaccine provides long-term protective immunity against SARS-CoV-2 in mice and nonhuman primates</article-title><source>Vaccines</source><volume>9</volume><issue>4</issue><year>2021</year><fpage>307</fpage><pub-id pub-id-type="pmid">33804981</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9040307</pub-id><pub-id pub-id-type="pmcid">PMC8063950</pub-id></element-citation></ref><ref id="bb0405"><label>81</label><element-citation publication-type="journal" id="rf202108140430010400"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maruggi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Shan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name></person-group><article-title>Advances in mRNA vaccines for infectious diseases</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>594</fpage><pub-id pub-id-type="pmid">30972078</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmcid">PMC6446947</pub-id></element-citation></ref><ref id="bb0410"><label>82</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name name-style="western"><surname>Hassett</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Benenato</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Jacquinet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.</given-names></name><name name-style="western"><surname>Woods</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yuzhakov</surname><given-names>O.</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Deterling</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geilich</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Ketova</surname><given-names>T.</given-names></name></person-group><article-title>Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines</article-title><source>Mol. Ther. Nucleic Acids</source><volume>15</volume><year>2019</year><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">30785039</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.omtn.2019.01.013</pub-id><pub-id pub-id-type="pmcid">PMC6383180</pub-id></element-citation></ref><ref id="bb0415"><label>83</label><element-citation publication-type="journal" id="rf202108140451105403"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Naradikian</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Parkhouse</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cain</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.</given-names></name><name name-style="western"><surname>Moody</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Verkerke</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Myles</surname><given-names>A.</given-names></name><name name-style="western"><surname>Willis</surname><given-names>E.</given-names></name></person-group><article-title>Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses</article-title><source>J. Exp. Med.</source><volume>215</volume><issue>6</issue><year>2018</year><fpage>1571</fpage><lpage>1588</lpage><pub-id pub-id-type="pmid">29739835</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20171450</pub-id><pub-id pub-id-type="pmcid">PMC5987916</pub-id></element-citation></ref><ref id="bb0420"><label>84</label><element-citation publication-type="journal" id="rf202108140451154476"><person-group person-group-type="author"><name name-style="western"><surname>Presnyak</surname><given-names>V.</given-names></name><name name-style="western"><surname>Alhusaini</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kline</surname><given-names>N.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>D.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Graveley</surname><given-names>B.R.</given-names></name></person-group><article-title>Codon optimality is a major determinant of mRNA stability</article-title><source>Cell</source><volume>160</volume><issue>6</issue><year>2015</year><fpage>1111</fpage><lpage>1124</lpage><pub-id pub-id-type="pmid">25768907</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2015.02.029</pub-id><pub-id pub-id-type="pmcid">PMC4359748</pub-id></element-citation></ref><ref id="bb0425"><label>85</label><element-citation publication-type="journal" id="rf202108140343138536"><person-group person-group-type="author"><name name-style="western"><surname>Furuichi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>LaFiandra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Shatkin</surname><given-names>A.J.</given-names></name></person-group><article-title>5'-terminal structure and mRNA stability</article-title><source>Nature</source><volume>266</volume><issue>5599</issue><year>1977</year><fpage>235</fpage><lpage>239</lpage><pub-id pub-id-type="pmid">557727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/266235a0</pub-id></element-citation></ref><ref id="bb0430"><label>86</label><element-citation publication-type="journal" id="rf202108140344043269"><person-group person-group-type="author"><name name-style="western"><surname>Stepinski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Waddell</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stolarski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Darzynkiewicz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rhoads</surname><given-names>R.E.</given-names></name></person-group><article-title>Synthesis and properties of mRNAs containing the novel "anti-reverse" cap analogs 7-methyl (3'-O-methyl) GpppG and 7-methyl (3'-deoxy) GpppG</article-title><source>RNA</source><volume>7</volume><issue>10</issue><year>2001</year><fpage>1486</fpage><lpage>1495</lpage><pub-id pub-id-type="pmid">11680853</pub-id><pub-id pub-id-type="pmcid">PMC1370192</pub-id></element-citation></ref><ref id="bb0435"><label>87</label><element-citation publication-type="journal" id="rf202108140415142276"><person-group person-group-type="author"><name name-style="western"><surname>Schlake</surname><given-names>T.</given-names></name><name name-style="western"><surname>Thess</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fotin-Mleczek</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kallen</surname><given-names>K.-J.</given-names></name></person-group><article-title>Developing mRNA-vaccine technologies</article-title><source>RNA Biol.</source><volume>9</volume><issue>11</issue><year>2012</year><fpage>1319</fpage><lpage>1330</lpage><pub-id pub-id-type="pmid">23064118</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/rna.22269</pub-id><pub-id pub-id-type="pmcid">PMC3597572</pub-id></element-citation></ref><ref id="bb0440"><label>88</label><element-citation publication-type="journal" id="rf202108140415150251"><person-group person-group-type="author"><name name-style="western"><surname>An</surname><given-names>D.</given-names></name><name name-style="western"><surname>Frassetto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jacquinet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Eybye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Milano</surname><given-names>J.</given-names></name><name name-style="western"><surname>DeAntonis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nguyen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Laureano</surname><given-names>R.</given-names></name><name name-style="western"><surname>Milton</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sabnis</surname><given-names>S.</given-names></name></person-group><article-title>Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia</article-title><source>EBioMedicine</source><volume>45</volume><year>2019</year><fpage>519</fpage><lpage>528</lpage><pub-id pub-id-type="pmid">31303505</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2019.07.003</pub-id><pub-id pub-id-type="pmcid">PMC6642332</pub-id></element-citation></ref><ref id="bb0445"><label>89</label><element-citation publication-type="journal" id="rf202108140415135377"><person-group person-group-type="author"><name name-style="western"><surname>Espeseth</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Cejas</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Citron</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>DiStefano</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>C.</given-names></name><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Swoyer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Touch</surname><given-names>S.</given-names></name></person-group><article-title>Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection</article-title><source>NPJ Vaccines</source><volume>5</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">32128257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-020-0163-z</pub-id><pub-id pub-id-type="pmcid">PMC7021756</pub-id></element-citation></ref><ref id="bb0450"><label>90</label><element-citation publication-type="journal" id="rf202108140415158110"><person-group person-group-type="author"><name name-style="western"><surname>Feldman</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fuhr</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Panther</surname><given-names>L.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>M.</given-names></name><name name-style="western"><surname>Senn</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>M.</given-names></name><name name-style="western"><surname>Almarsson</surname><given-names>?.</given-names></name><name name-style="western"><surname>Pujar</surname><given-names>H.S.</given-names></name></person-group><article-title>mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials</article-title><source>Vaccine</source><volume>37</volume><issue>25</issue><year>2019</year><fpage>3326</fpage><lpage>3334</lpage><pub-id pub-id-type="pmid">31079849</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.04.074</pub-id></element-citation></ref><ref id="bb0455"><label>91</label><element-citation publication-type="journal" id="rf202108140423481266"><person-group person-group-type="author"><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>McCullough</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L.J.</given-names></name></person-group><article-title>An mRNA vaccine against SARS-CoV-2&#8212;preliminary report</article-title><source>N. Engl. J. Med.</source><volume>383</volume><year>2020</year><fpage>1920</fpage><lpage>1931</lpage><pub-id pub-id-type="pmid">32663912</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2022483</pub-id><pub-id pub-id-type="pmcid">PMC7377258</pub-id></element-citation></ref><ref id="bb0460"><label>92</label><element-citation publication-type="journal" id="rf202108140415179449"><person-group person-group-type="author"><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lyke</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Raabe</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R.</given-names></name><name name-style="western"><surname>Swanson</surname><given-names>K.A.</given-names></name></person-group><article-title>Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults</article-title><source>Nature</source><volume>586</volume><issue>7830</issue><year>2020</year><fpage>589</fpage><lpage>593</lpage><pub-id pub-id-type="pmid">32785213</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2639-4</pub-id></element-citation></ref><ref id="bb0465"><label>93</label><element-citation publication-type="book" id="rf202108140415257710"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R.</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mulligan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R.</given-names></name></person-group><part-title>RNA-based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study</part-title><year>2020</year><publisher-name>Medrxiv</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id><pub-id pub-id-type="pmid">33053279</pub-id></element-citation></ref><ref id="bb0470"><label>94</label><element-citation publication-type="journal" id="rf202108140415264046"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Widge</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Denison</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Pruijssers</surname><given-names>A.J.</given-names></name></person-group><article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title><source>N. Engl. J. Med.</source><volume>383</volume><issue>25</issue><year>2020</year><fpage>2427</fpage><lpage>2438</lpage><pub-id pub-id-type="pmid">32991794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2028436</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id></element-citation></ref><ref id="bb0475"><label>95</label><element-citation publication-type="journal" id="rf202108140415279836"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Foulds</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Francica</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Werner</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Flach</surname><given-names>B.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bock</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Minai</surname><given-names>M.</given-names></name></person-group><article-title>Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates</article-title><source>N. Engl. J. Med.</source><volume>383</volume><issue>16</issue><year>2020</year><fpage>1544</fpage><lpage>1555</lpage><pub-id pub-id-type="pmid">32722908</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2024671</pub-id><pub-id pub-id-type="pmcid">PMC7449230</pub-id></element-citation></ref><ref id="bb0480"><label>96</label><element-citation publication-type="journal" id="rf202108140415381740"><person-group person-group-type="author"><name name-style="western"><surname>Silveira</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>G.M.S.G.</given-names></name><name name-style="western"><surname>Mendon&#231;a</surname><given-names>M.</given-names></name></person-group><article-title>DNA vaccines against COVID-19: perspectives and challenges</article-title><source>Life Sci.</source><volume>118919</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2020.118919</pub-id><pub-id pub-id-type="pmcid">PMC7749647</pub-id><pub-id pub-id-type="pmid">33352173</pub-id></element-citation></ref><ref id="bb0485"><label>97</label><element-citation publication-type="journal" id="rf202108140415480710"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Channappanavar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tasneem</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.-T.K.</given-names></name></person-group><article-title>Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus</article-title><source>Cell. Mol. Immunol.</source><volume>13</volume><issue>2</issue><year>2016</year><fpage>180</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">25640653</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cmi.2015.03</pub-id><pub-id pub-id-type="pmcid">PMC4786625</pub-id></element-citation></ref><ref id="bb0490"><label>98</label><element-citation publication-type="journal" id="rf202108140415337608"><person-group person-group-type="author"><name name-style="western"><surname>Adney</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Van Doremalen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.-P.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Bushmaker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas</article-title><source>Viruses</source><volume>11</volume><issue>3</issue><year>2019</year><fpage>212</fpage><pub-id pub-id-type="pmid">30832356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v11030212</pub-id><pub-id pub-id-type="pmcid">PMC6466352</pub-id></element-citation></ref><ref id="bb0495"><label>99</label><element-citation publication-type="journal" id="rf202108140344066545"><person-group person-group-type="author"><name name-style="western"><surname>Jiaming</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yanfeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yawei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Linlin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baoying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jinghua</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Chuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wenjie</surname><given-names>T.</given-names></name></person-group><article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title><source>Vaccine</source><volume>35</volume><issue>1</issue><year>2017</year><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.11.064</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></element-citation></ref><ref id="bb0500"><label>100</label><element-citation publication-type="journal" id="rf202108140343247754"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen</article-title><source>PLoS One</source><volume>9</volume><issue>11</issue><year>2014</year><object-id pub-id-type="publisher-id">e112602</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0112602</pub-id><pub-id pub-id-type="pmcid">PMC4236105</pub-id><pub-id pub-id-type="pmid">25405618</pub-id></element-citation></ref><ref id="bb0505"><label>101</label><element-citation publication-type="journal" id="rf202108140343402176"><person-group person-group-type="author"><name name-style="western"><surname>Bisht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group><article-title>Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein</article-title><source>Virology</source><volume>334</volume><issue>2</issue><year>2005</year><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">15780866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2005.01.042</pub-id><pub-id pub-id-type="pmcid">PMC7111832</pub-id></element-citation></ref><ref id="bb0510"><label>102</label><element-citation publication-type="journal" id="rf202108140343415801"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name></person-group><article-title>Intranasal protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</article-title><source>Vaccine</source><volume>25</volume><issue>34</issue><year>2007</year><fpage>6334</fpage><lpage>6340</lpage><pub-id pub-id-type="pmid">17640780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.06.017</pub-id><pub-id pub-id-type="pmcid">PMC7115497</pub-id></element-citation></ref><ref id="bb0515"><label>103</label><mixed-citation publication-type="other" id="or0005">WHO https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines.</mixed-citation></ref><ref id="bb0520"><label>104</label><element-citation publication-type="journal" id="rf202108140343481031"><person-group person-group-type="author"><name name-style="western"><surname>Magnusson</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Altenburg</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Bengtsson</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Bosman</surname><given-names>F.</given-names></name><name name-style="western"><surname>de Vries</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Rimmelzwaan</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Stertman</surname><given-names>L.</given-names></name></person-group><article-title>Matrix-M&#8482; adjuvant enhances immunogenicity of both protein-and modified vaccinia virus Ankara-based influenza vaccines in mice</article-title><source>Immunol. Res.</source><volume>66</volume><issue>2</issue><year>2018</year><fpage>224</fpage><lpage>233</lpage><pub-id pub-id-type="pmid">29594879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12026-018-8991-x</pub-id><pub-id pub-id-type="pmcid">PMC5899102</pub-id></element-citation></ref><ref id="bb0525"><label>105</label><element-citation publication-type="book" id="rf202108140415517293"><person-group person-group-type="author"><name name-style="western"><surname>Korber</surname><given-names>B.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gnanakaran</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>H.</given-names></name><name name-style="western"><surname>Theiler</surname><given-names>J.</given-names></name><name name-style="western"><surname>Abfalterer</surname><given-names>W.</given-names></name><name name-style="western"><surname>Foley</surname><given-names>B.</given-names></name><name name-style="western"><surname>Giorgi</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.D.</given-names></name></person-group><part-title>Spike Mutation Pipeline Reveals the Emergence of a More Transmissible Form of SARS-CoV-2</part-title><year>2020</year><publisher-name>BioRxiv</publisher-name></element-citation></ref><ref id="bb0530"><label>106</label><element-citation publication-type="journal" id="rf202108140343529025"><person-group person-group-type="author"><name name-style="western"><surname>Makhoul</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ayoub</surname><given-names>H.H.</given-names></name><name name-style="western"><surname>Chemaitelly</surname><given-names>H.</given-names></name><name name-style="western"><surname>Seedat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mumtaz</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Al-Omari</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abu-Raddad</surname><given-names>L.J.</given-names></name></person-group><article-title>Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses</article-title><source>Vaccines</source><volume>8</volume><issue>4</issue><year>2020</year><fpage>668</fpage><pub-id pub-id-type="pmid">33182403</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines8040668</pub-id><pub-id pub-id-type="pmcid">PMC7712303</pub-id></element-citation></ref><ref id="bb0535"><label>107</label><element-citation publication-type="journal" id="rf202108140415536986"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sircar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kaushik</surname><given-names>R.</given-names></name><name name-style="western"><surname>Bhat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>K.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Ghoshal</surname><given-names>U.</given-names></name></person-group><article-title>Coronavirus disease pandemic (COVID-19): challenges and a global perspective</article-title><source>Pathogens</source><volume>9</volume><issue>7</issue><year>2020</year><fpage>519</fpage><pub-id pub-id-type="pmid">32605194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pathogens9070519</pub-id><pub-id pub-id-type="pmcid">PMC7400054</pub-id></element-citation></ref><ref id="bb0540"><label>108</label><element-citation publication-type="journal" id="rf202108140415533809"><person-group person-group-type="author"><name name-style="western"><surname>Asadi Faezi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gholizadeh</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sanogo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oumarou</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mohamed</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Cissoko</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saliou Sow</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keita</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Baye</surname><given-names>Y.A.M.</given-names></name><name name-style="western"><surname>Pagliano</surname><given-names>P.</given-names></name><name name-style="western"><surname>Akouda</surname><given-names>P.</given-names></name><name name-style="western"><surname>Soufiane</surname><given-names>S.</given-names></name><name name-style="western"><surname>Iknane</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Safiatou Diallo</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Gansane</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ali Khan</surname><given-names>B.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allahverdipour</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ganvarov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Soumar&#233;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Asgharzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Samadi Kafil</surname><given-names>H.</given-names></name></person-group><article-title>Peoples' attitude toward COVID-19 vaccine, acceptance, and social trust among african and Middle East countries</article-title><source>Health Promot. Perspect.</source><volume>11</volume><issue>2</issue><year>2021</year><fpage>171</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">34195040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.34172/hpp.2021.21</pub-id><pub-id pub-id-type="pmcid">PMC8233680</pub-id></element-citation></ref><ref id="bb0545"><label>109</label><element-citation publication-type="journal" id="rf202108140424041887"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>X.-W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>Q.-X.</given-names></name><name name-style="western"><surname>Song</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.-J.</given-names></name></person-group><article-title>Study on the resistance of severe acute respiratory syndrome-associated coronavirus</article-title><source>J. Virol. Methods</source><volume>126</volume><issue>1&#8211;2</issue><year>2005</year><fpage>171</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">15847934</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jviromet.2005.02.005</pub-id><pub-id pub-id-type="pmcid">PMC7112909</pub-id></element-citation></ref><ref id="bb0550"><label>110</label><element-citation publication-type="journal" id="rf202108140421494910"><person-group person-group-type="author"><name name-style="western"><surname>Hassan</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Kafai</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Dmitriev</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Harvey</surname><given-names>I.B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Wessel</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Case</surname><given-names>J.B.</given-names></name></person-group><article-title>A single-dose intranasal ChAd vaccine protects upper and lower respiratory tracts against SARS-CoV-2</article-title><source>Cell</source><volume>183</volume><issue>1</issue><year>2020</year><fpage>169</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">32931734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.08.026</pub-id><pub-id pub-id-type="pmcid">PMC7437481</pub-id></element-citation></ref><ref id="bb0555"><label>111</label><element-citation publication-type="journal" id="rf202108140340051690"><person-group person-group-type="author"><name name-style="western"><surname>Gothelf</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gehl</surname><given-names>J.</given-names></name></person-group><article-title>What you always needed to know about electroporation based DNA vaccines</article-title><source>Hum. Vaccines Immunother.</source><volume>8</volume><issue>11</issue><year>2012</year><fpage>1694</fpage><lpage>1702</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.22062</pub-id><pub-id pub-id-type="pmcid">PMC3601144</pub-id><pub-id pub-id-type="pmid">23111168</pub-id></element-citation></ref><ref id="bb0560"><label>112</label><element-citation publication-type="journal" id="rf202108140415556244"><person-group person-group-type="author"><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Leist</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Abiona</surname><given-names>O.M.</given-names></name><name name-style="western"><surname>Boyoglu-Barnum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gillespie</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Himansu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sch&#228;fer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ziwawo</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>DiPiazza</surname><given-names>A.T.</given-names></name></person-group><article-title>SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness</article-title><source>Nature</source><volume>586</volume><issue>7830</issue><year>2020</year><fpage>567</fpage><lpage>571</lpage><pub-id pub-id-type="pmid">32756549</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2622-0</pub-id><pub-id pub-id-type="pmcid">PMC7581537</pub-id></element-citation></ref><ref id="bb0565"><label>113</label><element-citation publication-type="journal" id="rf202108140344138424"><person-group person-group-type="author"><name name-style="western"><surname>Sharpe</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Gilbride</surname><given-names>C.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>E.</given-names></name><name name-style="western"><surname>Belij-Rammerstorfer</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bissett</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lambe</surname><given-names>T.</given-names></name></person-group><article-title>The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world</article-title><source>Immunology</source><volume>160</volume><issue>3</issue><year>2020</year><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">32460358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.13222</pub-id><pub-id pub-id-type="pmcid">PMC7283842</pub-id></element-citation></ref><ref id="bb0570"><label>114</label><element-citation publication-type="journal" id="rf202108140344173762"><person-group person-group-type="author"><name name-style="western"><surname>Morris</surname><given-names>K.V.</given-names></name></person-group><article-title>The improbability of the rapid development of a vaccine for SARS-CoV-2</article-title><source>Mol. Ther.</source><volume>28</volume><issue>7</issue><year>2020</year><fpage>1548</fpage><lpage>1549</lpage><pub-id pub-id-type="pmid">32533920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ymthe.2020.06.005</pub-id><pub-id pub-id-type="pmcid">PMC7291966</pub-id></element-citation></ref><ref id="bb0575"><label>115</label><element-citation publication-type="book" id="rf202108140421508158"><person-group person-group-type="author"><name name-style="western"><surname>Quinlan</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Mou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ojha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Parcells</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>G.</given-names></name></person-group><part-title>The SARS-CoV-2 Receptor-binding Domain Elicits a Potent Neutralizing Response Without Antibody-dependent Enhancement</part-title><year>2020</year></element-citation></ref><ref id="bb0580"><label>116</label><element-citation publication-type="journal" id="rf202108140344181830"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Wheatley</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Kent</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>DeKosky</surname><given-names>B.J.</given-names></name></person-group><article-title>Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies</article-title><source>Nat. Microbiol.</source><volume>5</volume><issue>10</issue><year>2020</year><fpage>1185</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">32908214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-00789-5</pub-id><pub-id pub-id-type="pmcid">PMC12103240</pub-id></element-citation></ref><ref id="bb0585"><label>117</label><element-citation publication-type="journal" id="rf202108140344216658"><person-group person-group-type="author"><name name-style="western"><surname>van Riel</surname><given-names>D.</given-names></name><name name-style="western"><surname>de Wit</surname><given-names>E.</given-names></name></person-group><article-title>Next-generation vaccine platforms for COVID-19</article-title><source>Nat. Mater.</source><volume>19</volume><issue>8</issue><year>2020</year><fpage>810</fpage><lpage>812</lpage><pub-id pub-id-type="pmid">32704139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41563-020-0746-0</pub-id></element-citation></ref><ref id="bb0590"><label>118</label><element-citation publication-type="journal" id="rf202108140415547653"><person-group person-group-type="author"><name name-style="western"><surname>Zenuz</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Eslami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Safari E</surname><given-names>M.A.</given-names></name></person-group><article-title>The application of antimicrobial photodynamic therapy on Pseudomonas aeuroginosa and Enterococcus fecalis using hypericin and methylene blue photosensitizers</article-title><source>Biomed. Pharmacol. J.</source><volume>9</volume><issue>2</issue><year>2016</year><fpage>443</fpage><lpage>450</lpage></element-citation></ref><ref id="bb0595"><label>119</label><element-citation publication-type="journal" id="rf202108140440181158"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees</article-title><source>Nature</source><year>2020</year><fpage>321</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-020-00751-9</pub-id><pub-id pub-id-type="pmid">32179860</pub-id></element-citation></ref><ref id="bb0600"><label>120</label><element-citation publication-type="journal" id="rf202108140421532578"><person-group person-group-type="author"><name name-style="western"><surname>Barach</surname><given-names>P.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Brophy</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>D.Z.</given-names></name><name name-style="western"><surname>Lipshultz</surname><given-names>S.E.</given-names></name></person-group><article-title>Disruption of healthcare: will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?</article-title><source>Prog. Pediatr. Cardiol.</source><volume>59</volume><year>2020</year><fpage>101254</fpage><pub-id pub-id-type="pmid">32837144</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ppedcard.2020.101254</pub-id><pub-id pub-id-type="pmcid">PMC7274978</pub-id></element-citation></ref><ref id="bb0605"><label>121</label><element-citation publication-type="book" id="rf202108140424124168"><person-group person-group-type="author"><name name-style="western"><surname>Chohan</surname><given-names>U.W.</given-names></name></person-group><part-title>Coronavirus &amp; Vaccine Nationalism</part-title><year>2021</year></element-citation></ref><ref id="bb0610"><label>122</label><element-citation publication-type="book" id="rf202108140424409270"><person-group person-group-type="author"><name name-style="western"><surname>Fidler</surname><given-names>D.P.</given-names></name></person-group><part-title>Vaccine Nationalism's Politics</part-title><year>2020</year><publisher-name>American Association for the Advancement of Science</publisher-name></element-citation></ref><ref id="bb0615"><label>123</label><element-citation publication-type="journal" id="rf202108140416244300"><person-group person-group-type="author"><name name-style="western"><surname>Saeed</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sherdil</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ashraf</surname><given-names>U.</given-names></name><name name-style="western"><surname>Younas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Butt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S.</given-names></name></person-group><article-title>Identification of potential lockdown areas during COVID-19 transmission in Punjab,Pakistan</article-title><source>Public Health</source><volume>190</volume><year>2021</year><fpage>42</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">33338902</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.puhe.2020.10.026</pub-id><pub-id pub-id-type="pmcid">PMC7654357</pub-id></element-citation></ref><ref id="bb0620"><label>124</label><element-citation publication-type="journal" id="rf202108140436327046"><person-group person-group-type="author"><name name-style="western"><surname>Salamzadeh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dana</surname><given-names>L.P.</given-names></name></person-group><article-title>The coronavirus (COVID-19) pandemic: challenges among Iranian startups</article-title><source>J. Small Bus. Entrep.</source><year>2020</year><fpage>1</fpage><lpage>24</lpage></element-citation></ref><ref id="bb0625"><label>125</label><element-citation publication-type="journal" id="rf202108140422059435"><person-group person-group-type="author"><name name-style="western"><surname>Hussain</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Muhammad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Umer</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Omarkhail</surname><given-names>A.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kamran</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rashid</surname><given-names>H.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>Z.</given-names></name></person-group><article-title>Coronavirus disease 2019 in 5 neighboring limited-resource countries: a financial and health threat</article-title><source>Value. Health Reg. Issues</source><volume>24</volume><year>2021</year><fpage>114</fpage><lpage>116</lpage><pub-id pub-id-type="pmid">33545492</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vhri.2020.06.001</pub-id><pub-id pub-id-type="pmcid">PMC7324313</pub-id></element-citation></ref><ref id="bb0630"><label>126</label><element-citation publication-type="book" id="rf202108140422234715"><person-group person-group-type="author"><name name-style="western"><surname>Hitchings</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ranzani</surname><given-names>O.T.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Almiron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Said</surname><given-names>R.</given-names></name><name name-style="western"><surname>Borg</surname><given-names>R.</given-names></name><name name-style="western"><surname>Schulz</surname><given-names>W.L.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>P.V.</given-names></name></person-group><part-title>Effectiveness of CoronaVac in the Setting of High SARS-CoV-2 P. 1 Variant Transmission in Brazil: A Test-negative Case-control Study</part-title><year>2021</year><publisher-name>medRxiv</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lana.2021.100025</pub-id><pub-id pub-id-type="pmcid">PMC8310555</pub-id><pub-id pub-id-type="pmid">34386791</pub-id></element-citation></ref><ref id="bb0635"><label>127</label><element-citation publication-type="journal" id="rf202108140417229779"><person-group person-group-type="author"><name name-style="western"><surname>Tanriover</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Doganay</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Akova</surname><given-names>M.</given-names></name><name name-style="western"><surname>G&#252;ner</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Azap</surname><given-names>A.</given-names></name><name name-style="western"><surname>Akhan</surname><given-names>S.</given-names></name><name name-style="western"><surname>K&#246;se</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erdin&#231;</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Akalin</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Tabak</surname><given-names>&#214;.F.</given-names></name></person-group><article-title>Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey</article-title><source>Lancet</source><volume>398</volume><year>2021</year><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">34246358</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01429-X</pub-id><pub-id pub-id-type="pmcid">PMC8266301</pub-id></element-citation></ref><ref id="bb0640"><label>128</label><element-citation publication-type="journal" id="rf202108140417236972"><person-group person-group-type="author"><name name-style="western"><surname>Jara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Undurraga</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paredes</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fontecilla</surname><given-names>T.</given-names></name><name name-style="western"><surname>Jara</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pizarro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Acevedo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Leo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>F.</given-names></name></person-group><article-title>Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile</article-title><source>N. Engl. J. Med.</source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107715</pub-id><pub-id pub-id-type="pmcid">PMC8279092</pub-id><pub-id pub-id-type="pmid">34233097</pub-id></element-citation></ref><ref id="bb0645"><label>129</label><element-citation publication-type="journal" id="rf202108140436415782"><person-group person-group-type="author"><name name-style="western"><surname>Quagliariello</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aloisio</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bozzi Cionci</surname><given-names>N.</given-names></name><name name-style="western"><surname>Luiselli</surname><given-names>D.</given-names></name><name name-style="western"><surname>D'Auria</surname><given-names>G.</given-names></name><name name-style="western"><surname>Martinez-Priego</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perez-Villarroya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Langerholc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Primec</surname><given-names>M.</given-names></name><name name-style="western"><surname>Micetic-Turk</surname><given-names>D.</given-names></name><name name-style="western"><surname>Di Gioia</surname><given-names>D.</given-names></name></person-group><article-title>Effect of Bifidobacterium breve on the intestinal microbiota of coeliac children on a gluten free diet: a pilot study</article-title><source>Nutrients</source><volume>8</volume><issue>10</issue><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/nu8100660</pub-id><pub-id pub-id-type="pmcid">PMC5084046</pub-id><pub-id pub-id-type="pmid">27782071</pub-id></element-citation></ref><ref id="bb0650"><label>130</label><element-citation publication-type="journal" id="rf202108140417226638"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ganneru</surname><given-names>B.</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Raju</surname><given-names>D.</given-names></name><name name-style="western"><surname>Praturi</surname><given-names>U.</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>C.</given-names></name><name name-style="western"><surname>Redkar</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Gillurkar</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Kushwaha</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Mohapatra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bhate</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>S.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ella</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bhargava</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vadrevu</surname><given-names>K.M.</given-names></name></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial</article-title><source>Lancet Infect. Dis.</source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00070-0</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id><pub-id pub-id-type="pmid">33705727</pub-id></element-citation></ref><ref id="bb0655"><label>131</label><element-citation publication-type="journal" id="rf202108140436424081"><person-group person-group-type="author"><name name-style="western"><surname>Memar</surname><given-names>M.Y.</given-names></name><name name-style="western"><surname>Varshochi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shokouhi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Asgharzadeh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Procalcitonin: the marker of pediatric bacterial infection</article-title><source>Biomed. Pharmacother.</source><volume>96</volume><year>2017</year><fpage>936</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">29203386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2017.11.149</pub-id></element-citation></ref><ref id="bb0660"><label>132</label><element-citation publication-type="journal" id="rf202108140424553083"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.-C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.-H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.-H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.-J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.-P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.-S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>Lancet</source><volume>395</volume><issue>10240</issue><year>2020</year><fpage>1845</fpage><lpage>1854</lpage><pub-id pub-id-type="pmid">32450106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id></element-citation></ref><ref id="bb0665"><label>133</label><element-citation publication-type="journal" id="rf202108140417278488"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.A.C.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Barnabas</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.E.</given-names></name></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil,South Africa, and the UK</article-title><source>Lancet</source><volume>397</volume><issue>10269</issue><year>2021</year><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="bb0670"><label>134</label><element-citation publication-type="journal" id="rf202108140422173017"><person-group person-group-type="author"><name name-style="western"><surname>Emary</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Golubchik</surname><given-names>T.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Ariani</surname><given-names>C.V.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Blane</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bonsall</surname><given-names>D.</given-names></name><name name-style="western"><surname>Cicconi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Charlton</surname><given-names>S.</given-names></name></person-group><article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1. 7): an exploratory analysis of a randomised controlled trial</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>1351</fpage><lpage>1362</lpage><pub-id pub-id-type="pmid">33798499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00628-0</pub-id><pub-id pub-id-type="pmcid">PMC8009612</pub-id></element-citation></ref><ref id="bb0675"><label>135</label><element-citation publication-type="book" id="rf202108140422252675"><person-group person-group-type="author"><name name-style="western"><surname>Bernal</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thelwall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dabrera</surname><given-names>G.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>R.</given-names></name></person-group><part-title>Effectiveness of COVID-19 Vaccines Against the B. 1.617. 2 Variant</part-title><year>2021</year><publisher-name>medRxiv</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2108891</pub-id><pub-id pub-id-type="pmcid">PMC8314739</pub-id><pub-id pub-id-type="pmid">34289274</pub-id></element-citation></ref><ref id="bb0680"><label>136</label><element-citation publication-type="journal" id="rf202108140417313774"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Tukhvatullin</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Grousova</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Erokhova</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kovyrshina</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Botikov</surname><given-names>A.G.</given-names></name></person-group><article-title>Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia</article-title><source>Lancet</source><volume>396</volume><issue>10255</issue><year>2020</year><fpage>887</fpage><lpage>897</lpage><pub-id pub-id-type="pmid">32896291</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31866-3</pub-id><pub-id pub-id-type="pmcid">PMC7471804</pub-id></element-citation></ref><ref id="bb0685"><label>137</label><element-citation publication-type="journal" id="rf202108140451111260"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>I.V.</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>D.V.</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>O.V.</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Kovyrshina</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Lubenets</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Grousova</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Erokhova</surname><given-names>A.S.</given-names></name></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><volume>397</volume><issue>10275</issue><year>2021</year><fpage>671</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></element-citation></ref><ref id="bb0690"><label>138</label><element-citation publication-type="journal" id="rf202108140450409575"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Heerwegh</surname><given-names>D.</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Groot</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Stoop</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tete</surname><given-names>S.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>I.</given-names></name></person-group><article-title>Interim results of a phase 1&#8211;2a trial of Ad26. COV2. S Covid-19 vaccine</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>1824</fpage><lpage>1835</lpage><pub-id pub-id-type="pmid">33440088</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034201</pub-id><pub-id pub-id-type="pmcid">PMC7821985</pub-id></element-citation></ref><ref id="bb0695"><label>139</label><element-citation publication-type="journal" id="rf202108140417346085"><person-group person-group-type="author"><name name-style="western"><surname>Mercado</surname><given-names>N.B.</given-names></name><name name-style="western"><surname>Zahn</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wegmann</surname><given-names>F.</given-names></name><name name-style="western"><surname>Loos</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chandrashekar</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>L.</given-names></name><name name-style="western"><surname>McMahan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tostanoski</surname><given-names>L.H.</given-names></name></person-group><article-title>Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques</article-title><source>Nature</source><volume>586</volume><issue>7830</issue><year>2020</year><fpage>583</fpage><lpage>588</lpage><pub-id pub-id-type="pmid">32731257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2607-z</pub-id><pub-id pub-id-type="pmcid">PMC7581548</pub-id></element-citation></ref><ref id="bb0700"><label>140</label><element-citation publication-type="journal" id="rf202108140417371691"><person-group person-group-type="author"><name name-style="western"><surname>Oliver</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Gargano</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Scobie</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hadler</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Blain</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>McClung</surname><given-names>N.</given-names></name><name name-style="western"><surname>Campos-Outcalt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Morgan</surname><given-names>R.L.</given-names></name></person-group><article-title>The advisory committee on immunization practices&#8217; interim recommendation for use of janssen COVID-19 Vaccine&#8212;United States, february 2021</article-title><source>Morb. Mortal. Wkly Rep.</source><volume>70</volume><issue>9</issue><year>2021</year><fpage>329</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7009e4</pub-id><pub-id pub-id-type="pmcid">PMC7948932</pub-id><pub-id pub-id-type="pmid">33661860</pub-id></element-citation></ref><ref id="bb0705"><label>141</label><element-citation publication-type="journal" id="rf202108140417385850"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>C&#225;rdenas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goepfert</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fennema</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spiessens</surname><given-names>B.</given-names></name><name name-style="western"><surname>Offergeld</surname><given-names>K.</given-names></name><name name-style="western"><surname>Scheper</surname><given-names>G.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Robb</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Treanor</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barouch</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Stoddard</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ryser</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Marovich</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Neuzil</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Corey</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cauwenberghs</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tanner</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hardt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ruiz-Gui&#241;az&#250;</surname><given-names>J.</given-names></name><name name-style="western"><surname>Le Gars</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schuitemaker</surname><given-names>H.</given-names></name><name name-style="western"><surname>Van Hoof</surname><given-names>J.</given-names></name><name name-style="western"><surname>Struyf</surname><given-names>F.</given-names></name><name name-style="western"><surname>Douoguih</surname><given-names>M.</given-names></name></person-group><article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19</article-title><source>N. Engl. J. Med.</source><volume>384</volume><year>2021</year><fpage>2187</fpage><lpage>2201</lpage><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="bb0710"><label>142</label><element-citation publication-type="journal" id="rf202108140417414239"><person-group person-group-type="author"><name name-style="western"><surname>Keijser</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Zaura</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huse</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>van der Vossen</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schuren</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Montijn</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>ten Cate</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Crielaard</surname><given-names>W.</given-names></name></person-group><article-title>Pyrosequencing analysis of the oral microflora of healthy adults</article-title><source>J. Dent. Res.</source><volume>87</volume><issue>11</issue><year>2008</year><fpage>1016</fpage><lpage>1020</lpage><pub-id pub-id-type="pmid">18946007</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/154405910808701104</pub-id></element-citation></ref><ref id="bb0715"><label>143</label><element-citation publication-type="book" id="rf202108140422262681"><person-group person-group-type="author"><name name-style="western"><surname>Dey</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rajanathan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pericherla</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Choonia</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Bajpai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Sinha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saini</surname><given-names>G.</given-names></name></person-group><part-title>Immunogenic Potential of DNA Vaccine Candidate, ZyCoV-D Against SARS-CoV-2 in Animal Models</part-title><year>2021</year><publisher-name>bioRxiv</publisher-name><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2021.05.098</pub-id><pub-id pub-id-type="pmcid">PMC8166516</pub-id><pub-id pub-id-type="pmid">34120764</pub-id></element-citation></ref><ref id="bb0720"><label>144</label><element-citation publication-type="journal" id="rf202108140417406084"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Alekseyenko</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Gapstur</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Purdue</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Abnet</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Stolzenberg-Solomon</surname><given-names>R.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ravel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J.</given-names></name></person-group><article-title>Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study</article-title><source>Gut</source><volume>67</volume><issue>1</issue><year>2018</year><fpage>120</fpage><lpage>127</lpage><pub-id pub-id-type="pmid">27742762</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/gutjnl-2016-312580</pub-id><pub-id pub-id-type="pmcid">PMC5607064</pub-id></element-citation></ref><ref id="bb0725"><label>145</label><element-citation publication-type="journal" id="rf202108140344438266"><person-group person-group-type="author"><name name-style="western"><surname>Dagan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barda</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kepten</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miron</surname><given-names>O.</given-names></name><name name-style="western"><surname>Perchik</surname><given-names>S.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reis</surname><given-names>B.</given-names></name><name name-style="western"><surname>Balicer</surname><given-names>R.D.</given-names></name></person-group><article-title>BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting</article-title><source>N. Engl. J. Med.</source><volume>384</volume><issue>15</issue><year>2021</year><fpage>1412</fpage><lpage>1423</lpage><pub-id pub-id-type="pmid">33626250</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2101765</pub-id><pub-id pub-id-type="pmcid">PMC7944975</pub-id></element-citation></ref><ref id="bb0730"><label>146</label><element-citation publication-type="journal" id="rf202108140417395841"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Burgess</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Naleway</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Tyner</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Meece</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olsho</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Caban-Martinez</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Fowlkes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lutrick</surname><given-names>K.</given-names></name></person-group><article-title>Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers&#8212;eight US locations, December 2020&#8211;March 2021</article-title><source>Morb. Mortal. Wkly Rep.</source><volume>70</volume><issue>13</issue><year>2021</year><fpage>495</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7013e3</pub-id><pub-id pub-id-type="pmcid">PMC8022879</pub-id><pub-id pub-id-type="pmid">33793460</pub-id></element-citation></ref><ref id="bb0735"><label>147</label><element-citation publication-type="journal" id="rf202108140417447748"><person-group person-group-type="author"><name name-style="western"><surname>Frenck</surname><given-names>R.W.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Klein</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Walter</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Senders</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>R.</given-names></name></person-group><article-title>Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents</article-title><source>N. Engl. J. Med.</source><volume>385</volume><year>2021</year><fpage>239</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">34043894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107456</pub-id><pub-id pub-id-type="pmcid">PMC8174030</pub-id></element-citation></ref><ref id="bb0740"><label>148</label><element-citation publication-type="journal" id="rf202108140417428708"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N. Engl. J. Med.</source><volume>384</volume><issue>5</issue><year>2021</year><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="bb0745"><label>149</label><element-citation publication-type="journal" id="rf202108140417397781"><person-group person-group-type="author"><name name-style="western"><surname>Castillo</surname><given-names>G.D.V.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Sotomayor</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Azcurra</surname><given-names>A.I.</given-names></name></person-group><article-title>Study of virulence factor of Candida species in oral lesions and its association with potentially malignant and malignant lesions</article-title><source>Arch. Oral Biol.</source><volume>91</volume><year>2018</year><fpage>35</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">29656214</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.archoralbio.2018.02.012</pub-id></element-citation></ref><ref id="bb0750"><label>150</label><element-citation publication-type="journal" id="rf202108140450098452"><person-group person-group-type="author"><name name-style="western"><surname>Giuliani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Troiano</surname><given-names>G.</given-names></name><name name-style="western"><surname>Cordaro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corsalini</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gioco</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lo Muzio</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pignatelli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lajolo</surname><given-names>C.</given-names></name></person-group><article-title>Rate of malignant transformation of oral Lichen planus: a systematic review</article-title><source>Oral Dis.</source><volume>8</volume><issue>10</issue><year>2018</year><fpage>12885</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/odi.12885</pub-id><pub-id pub-id-type="pmid">29738106</pub-id></element-citation></ref><ref id="bb0755"><label>151</label><element-citation publication-type="journal" id="rf202108140344451544"><person-group person-group-type="author"><name name-style="western"><surname>Mehrabani</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Karimian</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rakhshaei</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pakdel</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eslami</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fakhrzadeh</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rahimi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Salehi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kafil</surname><given-names>H.S.</given-names></name></person-group><article-title>Chitin/silk fibroin/TiO2 bio-nanocomposite as a biocompatible wound dressing bandage with strong antimicrobial activity</article-title><source>Int. J. Biol. Macromol.</source><volume>116</volume><year>2018</year><fpage>966</fpage><lpage>976</lpage><pub-id pub-id-type="pmid">29782987</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijbiomac.2018.05.102</pub-id></element-citation></ref><ref id="bb0760"><label>152</label><element-citation publication-type="journal" id="rf202108140425037515"><person-group person-group-type="author"><name name-style="western"><surname>Heath</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Galiza</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Boffito</surname><given-names>M.</given-names></name><name name-style="western"><surname>Browne</surname><given-names>D.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chadwick</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Clark</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cosgrove</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galloway</surname><given-names>J.</given-names></name></person-group><article-title>Safety and efficacy of NVX-CoV2373 Covid-19 vaccine</article-title><source>N. Engl. J. Med.</source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2107659</pub-id><pub-id pub-id-type="pmcid">PMC8262625</pub-id><pub-id pub-id-type="pmid">34192426</pub-id></element-citation></ref><ref id="bb0765"><label>153</label><element-citation publication-type="book" id="rf202108140422347603"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Gobeil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Seguin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Atkins</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boulay</surname><given-names>I.</given-names></name><name name-style="western"><surname>Charbonneau</surname><given-names>P.-Y.</given-names></name><name name-style="western"><surname>Couture</surname><given-names>M.</given-names></name><name name-style="western"><surname>D'Aoust</surname><given-names>M.-A.</given-names></name><name name-style="western"><surname>Dhaliwall</surname><given-names>J.</given-names></name><name name-style="western"><surname>Finkle</surname><given-names>C.</given-names></name></person-group><part-title>Phase 1 Trial of a Candidate Recombinant Virus-like Particle Vaccine for Covid-19 Disease Produced in Plants</part-title><year>2020</year><publisher-name>medRxiv</publisher-name></element-citation></ref></ref-list><ack id="ac0005"><title>Acknowledgment</title><p id="p0060">This study was supported by <funding-source id="gts0005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004484</institution-id><institution>TUMS</institution></institution-wrap></funding-source> with Grant number 67235 and was approved by local ethic committee with registration number IR.TBZMED.REC.1399.1071. We thank all authors who provided their data to enrich this study and we hope this study help termination of Covid-19 pandemic soon.</p></ack></back></article></pmc-articleset>